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ABSTRACT
The aim of effective cancer treatment is to prolong the patients’ life while offering a
reasonable quality of life during and after treatment. The treatments must carry their ac-
tions/effects in a manner such that a very large percentage of tumor cells die or shift into a
state where they stop proliferating. The fundamental issue in systems biology is to model
gene interaction via gene regulatory networks (GRN) and hence provide an informatics
environment to study the effects of gene mutation as well as derive newer and effective
intervention (via drugs) strategies to alter the cancerous state of the network, thereby erad-
icating the tumor. In this dissertation, we present two approaches to model gene regulatory
networks. These approach are different, albeit having a common structure to them.
We develop the GRN under a Boolean formalism with deterministic and stochastic
framework. The knowledge used to model these networks are derived from biological
pathways, which are partial and incomplete. This work is an attempt towards understand-
ing the dynamics of a proliferating cell and to control this system. Initial part (determin-
istic) of this work focuses on formulating a deterministic model by assuming the pathway
regulations to be complete and accurate. Using these models algorithms were developed to
pin-point faults (mutations) in the network and design personalized combination therapy
depending on the expression signature of specific output genes.
To introduce stochastic nature onto the model due to incompleteness in the prior bio-
logical knowledge, an uncertainty class of models was defined over the biological network.
Two such uncertainty class of models are modeled- one over the state transitions and the
other over the node transitions in the system. This knowledge is transferred to priors,
and the existing Bayesian theory is used to update and converge to a good model. The
Bayesian control theory for Markovian processes is applied to the problem of interven-
ii
tion in Markovian gene regulatory networks, while simultaneously updating the model.
Via a toy example, it is shown that effective prior knowledge quantification can signifi-
cantly help in converging on to the actual model with limited information from the system
and take advantage of the optimality promised by Bayesian intervention. These control
methods however, suffer from computational and memory complexity issues- Curse of Di-
mensionality, to be useful for any network size of biological relevance. To counter these
issues associated with Dynamic Programming, suboptimal approximate algorithm known
as Q-learning and its Bayesian variation are used to save on computational and memory
complexities. These sub-optimal approximate algorithms perform very close (but inferior)
to optimal policy, but the computational saving, both in terms of time and memory are
significant to extend them to networks of larger size.
iii
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NOMENCLATURE
Bach1: BTB and CNC homology 1, basic leucine zipper transcription factor 1
Nrf2: Nuclear factor (erythroid-derived 2)-like 2
PKC: Protein Kinase C
ROS: Reactive Oxygen Species
Keap1: Kelch-like ECH-associated protein 1
ARE: Anti-oxidant Response Element
Ras: Rat Sarcoma
PI3K: Phosphoinositide 3-kinase
PIP2: Phosphatidylinositol 4,5-bisphosphate
PIP3: Phosphatidylinositol (3,4,5)-trisphosphate
PTEN: Phosphatase and tensin homolog
ATM: Ataxia Telangiectasia Mutated
Akt: Protein Kinase B
Mdm2: mouse double minute 2
p53: Tumor protein 53
GSK-3β : Glycogen synthase kinase 3 beta
Bad: BCL2-associated agonist of cell death
Bcl-2: B-cell lymphoma 2
HIF: Hypoxia Inducible Factor
VHL: Von Hippel Lindau tumor suppressor protein
VEGF: Vascular Endothelial Growth Factor
ETC: Electron Transport Chain
HRE: Hypoxia Response Element
vii
PHD: Prolyl Hydroxylase Domain containing proteins
ARNT: Aryl Hydrocarbon Nuclear Trans locator
mRNA: messenger Ribo Nucleic Acid
NADH: Nicotine Amide Dinucleotide (reduced form)
FAD: Flavin Adenine Dinucleotide
GAPDH: Glyceraldehyde Phosphate Dehydrogenase
LDHA: Lactate Dehydrogenase A
PDH: Pyruvate Dehydrogenase
PDK: Pyruvate Dehydrogenase Kinase
ETC: Electron Transport Chain
ATP: Adenosine Tri Phosphate
ADP: Adenosine Di Phosphate
NAD: Nicotine Amide Dinucleotide
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1. INTRODUCTION
1.1 Systems Biology
Systems biology is a biology based interdisciplinary science that studies complex in-
teraction within biological systems using a systems or holistic approach. All the prop-
erties, both functional and behavioral, of a biological system are the end result of these
interactions. Consequently, precise qualitative and quantitative analysis will lead to newer
insights in understanding these systems. In experimental (molecular) biology, the aim is to
characterize the molecular constituents of living organisms. By contrast, systems biology
tries to treat cells as organized molecular systems. Several approaches in physiology have
taken a systems approach. There has been a surge in research in systems biology; this
primarily is due to limitations of non-systems approaches along with advances in lots of
associated fields such as computer science, genomics, nonlinear dynamical systems, con-
trol theory and Bayesian theory. Systems-level understanding is an imprecise notion due
to vagueness in defining the system. In this dissertation, we use gene regulatory networks
to define the system of interest. However, this is just one aspect of the system. The core
of any system is the dynamics it creates and the logic that creates these dynamics. Conse-
quently, in this study, we try to understand and model the logic that creates the dynamics
in a biological system. The 3 primary goals of systems biology namely, -Structure Iden-
tification, System Dynamics and System Intervention- are explained in detail. Flow chart
for systems biology research is shown in Fig. 1.1.
1.1.1 Structure Identification
The first step in any systems level study is to understand the physical structure of the
system. The physical structure will help us in identifying both direct and indirect influ-
ences between different components of the system. In a biological system (e.g. a cell),
1
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Figure 1.1: Flowchart of systems biology research
the gene regulatory network represents these details. The structure of such a network has
been obtained over decades of experimentation involving genes/ proteins of interests and
determining the regulatory relationships between them.
1.1.2 System Dynamics
Once the system structure is identified, the system dynamics need to be understood.
System dynamics will be mathematical equations representing the state transition of the
system given the current and previous states of the system along with all other pertinent
information. Intuitively, the state of the system gives us enough information to determine
the future course (states) of the system. The structure of the system directly influences the
dynamics of the system. One common feature in gene regulatory networks is the presence
of negative feedback connections which are important to maintain the stability of the sys-
tem. Such a configuration is very common in controls literature. This feedback feature
can give rise to oscillatory behavior.
2
1.1.3 System Intervention
The ultimate aim of the two study aspects discussed above is to successfully inter-
vene to alter the behavior of the system. We intend the system to be traversing through
states defined to be good rather than bad for a favorable outcome in these situations. In
systems biology, this translates to finding therapeutic approaches based on systems level
understanding such that there is a favorable prognosis of the ailment. Many of the present
day drugs have been developed through effect-oriented screening. It is only recently that
molecular targets of drugs have been identified and this information is being used to design
better targeted drugs. Success in these newly developed methods will need to exploit the
dynamics of the cell to accurately predict the effects of different interventions. This will
help us in differentiating favorable outcomes from unfavorable ones.
1.2 Cell Biology: The Living Cell
The word ’cell’ is derived from the Latin word ’cellula’ meaning a small room. A
cell is the most basic unit of life. A cell is the smallest unit capable to replicating itself.
Anything smaller than a cell is truly not living. An example of this are viruses which are
genetic material, but are not capable of replicating themselves. They usually hijack the
replicating machinery of their host to make more copies of themselves. A cell is typically
5-20µm in diameter. Cells are membrane bound units capable of performing different
functions. The simplified structure of a cell is shown in Fig. 1.2.
A brief description of the components are given below:
• Cell membrane: The cell membrane is the wall boundary surrounding the cell. It is
a selectively permeable membrane made up of lipid bilayer and embedded proteins.
All the compartments shown within the cell wall are called as organelles.
• Nucleus: It is the most important organelle and contains most of the genetic infor-
3
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Figure 1.2: A simplified human cell
mation or the DNA. Its function is to maintain integrity of the DNA and control the
activities by regulating the expressions of the genes.
• Nucleolus: It is a discrete densely stained structure within the nucleus. Its main role
is to assemble ribosomes and also to transcribe ribosomal RNA.
• Endoplasmic Reticulum (ER): This organelle is responsible for synthesizing and
transporting all the proteins, lipids and steroids. It also regulates drug metabolism
and attachment of receptors onto the cell membrane proteins.
• Ribosome: Ribosomes reads the mRNA and assembles the corresponding the pro-
tein sequence.
• Mitochondria: They are the powerhouse of the cell. They are responsible for con-
verting the glucose into ATP, which is used by the cells to meet its energy demand.
• Golgi apparatus: Its primary function is to process and package protein molecules
4
to be delivered elsewhere within the cell. They are also responsible for intra-cellular
communication.
• Lysosome: They destroy all cellular debris by using enzymes. It also helps the cell
make new organelles by destroying the old ones.
• Vacuoles: They are used for transporting toxic elements out of cell, maintaining pH
and pressure inside the cell.
1.3 DNA, RNA and Protein: Central Dogma of Biology
The ability of cells to sort, retrieve and translate the genetic information is critical for
making and maintaining a living organism. The information contained in each cell should
also be passed on to its daughter cells at each cell division and also from generation to
generation through the reproductive cells. Deoxyribonucleic acid (DNA) are the molecules
used to store such genetic information. The famous double strand representations used
everywhere is essentially representing the human DNA double-strand. The DNA molecule
is double stranded and each strand is composed of combination of 1 out of 4 nucleotides
at each position. The 4 nucleotide bases that make up the the DNA are Adenine (A),
Guanine (G), Cytosine (C) and Thymine (T). The double-strand of the DNA is maintained
due to complementary base-pairing property of the nucleotides- A pairs with T through a
double bond, while G pairs with C through a triple bond. These settings guarantee that
both the strands are equidistant apart all along the length of the DNA molecule. Fig. 1.3
shows the building blocks and single strand of DNA. Two such single strands can be
combined to obtain a double-stranded DNA with the pairing rule mentioned above and
shown in Fig. 1.4. This double-strand DNA molecule aligns itself in the form of the double
helix. Since DNA is double-stranded and satisfy base-pairing rule complete information
about one strand will completely determine the second strand of the DNA. The complete
information encoded within the DNA depends on the sequence of the each base A, G,
5
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Figure 1.3: Building block of DNA
C and T determines within the DNA. Human genome consists of about 3 billion base-
pairs. This can be thought to be a book consisting of 3 billion letters from the alphabet set
{A,G,C,T}. Difference across the different organisms is due to the fact that their DNA
sequence is different from each other.
Genes are short stretches of DNA nucleotides consisting of few thousand base-pairs.
The human genome consists of about roughly, 25000 genes. Different genes are of dif-
ferent lengths and each gene codes for a specific protein in the body. Genes hold all the
information to build and maintain a cell as well as pass this information to its offsprings.
Genes have regulatory regions that specify when and how much protein needs to be pro-
duced to meet the requirements of the cell. Additionally, there are coding and non-coding
regions in DNA. Coding sequence also known as exon are the useful region which are
known to participate in making the proteins. Non-coding regions also known as introns
do not have any participation in making the protein. The introns are also known as junk
DNA. Coding regions are shown in red and non-coding regions in green in Fig. 1.5.
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The word gene is derived from the Greek word genesis which means birth. DNA does
not produce the proteins directly, but uses another intermediate step to make them. This
intermediate step is where DNA is converted to another type of nucleic acid, RNA (ri-
bonucleic acid). When a particular protein is needed the double-stranded DNA is split and
the gene corresponding to the protein is copied into RNA. This process is referred to as
transcription. The cell then uses the copies of these RNA to create the protein and this
process is referred to as translation. The use of RNA helps in generating large quantities
of protein simultaneously. Each DNA can produce multiple copies of RNA and each RNA
can produce multiple molecules of the protein. The RNA nucleotides are also made up
of 4 bases- Adenine (A), Guanine (G), Cytosine (C) and Uracil (U). Unlike DNA, which
is double-stranded and helical in shape, RNA is single-stranded and can take a variety of
shapes. Once the DNA is transcribed into RNA the nucleotides are translated to the corre-
sponding protein. Proteins are made up of amino acids. A combination of 3 nucleotides in
the RNA describes a single amino acid. This nucleotide triplet is also known as a codon.
Since RNA is composed of 4 nucleotides a total of 64 codons are possible however, there
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Figure 1.5: Central dogma of molecular biology
are only 20 amino acids that exist in nature and this is due to the redundancy whereby
different combinations code for the same amino acid. Table. 1.1 gives all the nucleotide
combinations and the amino acids they represent. The central dogma of molecular biology
is an explanation of information flow in a biological system. It says that information flow
is from DNA→ RNA→ protein. It is pictorially shown in Fig. 1.5.
1.4 Pathways and Signal Transduction
In multi-cellular organisms, the activities of a cell are carried out by intra- and extra-
cellular cues and the signal it receives. Each cell has its own different functionality and its
future course is dependent on these signals. For example, whether a cell needs to prolifer-
ate or undergo programmed cell death (apoptosis) is dependent on a number of different
signals it receives. The state of a cell is tightly controlled by these different signals. In
a healthy system, there is a balance between the cell death, cell differentiation and cell
division. The regulation of these signals is lost in a disease like cancer and the presence
of this aberrant signaling makes a disease like cancer very difficult to cure. Cell signaling
through electrical pulses is primarily used by neuronal cells to communicate. However, for
somatic cells, proteins are used as the primary signaling molecules. Signaling molecules
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Table 1.1: Genetic code
Amino acid Codon(s)
Alanine/Ala/A GCU, GCC, GCA, GCG
Arginine/Arg/R CGU, CGC, CGA, CGG, AGA, AGG
Asparagine/Asn/N AAU, AAC
Asparticacid/Asp/D GAU, GAC
Cysteine/Cys/C UGU, UGC
Glutamine/Gln/Q CAA, CAG
Glutamicacid/Glu/E GAA, GAG
Glycine/Gly/G GGU, GGC, GGA, GGG
Histidine/His/H CAU, CAC
Isoleucine/Ile/I AUU, AUC, AUA
Leucine/Leu/L UUA, UUG, CUU, CUC, CUA, CUG
Lysine/Lys/K AAA, AAG
Methionine/Met/M AUG
Phenylalanine/Phe/F UUU, UUC
Proline/Pro/P CCU, CCC, CCA, CCG
Serine/Ser/S UCU, UCC, UCA, UCG, AGU, AGC
T hreonine/T hr/T ACU, ACC, ACA, ACG
Tryptophan/Trp/W UGG
Tyrosine/Tyr/Y UAU, UAC
Valine/Val/V GUU, GUC, GUA, GUG
Start AUG
Stop UAA, UGA, UAG
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usually function by changing the three dimensional (3-D) structure of the other molecules
to which it binds or communicates. These interactions are usually multivariate in the sense
that a single molecule can communicate with a number of other molecules and vice-versa.
Because of the inherent difficulty in understanding such information, biologists have used
the marginal interactions between these signaling molecules, collectively known as path-
way information. A pathway is a series of molecules in a cell which are interconnected
such that the change in the activity of one of the molecules can cause a change in the
activity of other molecules. Meanwhile, signal transduction occurs when a molecule, that
is extracellular, binds to a surface receptor in cell and triggers a series of changes in the
cell. This is the mechanism by which cells communicate with other cells as well as with
itself. A collection of many such pathway segments will constitute a graph/network which
indicates the regulatory relationships between the different interacting molecules in the
network. Such a network is also referred to as a gene regulatory network.
1.5 Homeostasis and Gene Regulation
Homeostasis, from the Greek word meaning similar or steady, is the property of a sys-
tem by which the variables are regulated in such a way that the system maintains fairly
stable conditions necessary for survival. This word was coined by Walter Cannon in 1926.
In the human body this might relate to maintaining the healthy levels of body temperature,
water, salt, sugar, protein, fat, calcium and oxygen contents in the blood. The regulatory
processes in the body, dynamically maintain the steady-state conditions in the system.
Norbert Weiner was able to relate the concepts of homeostasis in living tissues to that of
machines. Cybernetics borrows ideas from biology that any existing system has a natural
drive towards homeostasis. A simple example in this regard is the control of body tem-
perature close to 98.6oF. When the temperature increases we tend to sweat and when it
is too cold we sweat less and reduce blood circulation to prevent loss of heat. In a way
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living cells can also be thought up of as cybernetic systems. One fundamental feature in
such systems is the presence of negative feedback loops that always tend to counter the
externally acting force. The negative feedback arises out of imbalance between the forces
that tend to counter each other. Another important factor of these negative feedbacks is
that they give rise to oscillatory behavior. The negative feedback takes time to act and such
a time lag is also another essential feature of natural systems.
How do biological systems achieve homeostasis?
The most important method through which cells maintain homeostatic conditions is through
gene regulation. Of the roughly 25,000 genes present in a human cell, not all of them need
to be making protein all the time. A gene that is producing protein is said to be expressed,
while a gene not producing protein is said to be not expressed. The amount of protein
produced however, depends on the demand from the system. The regulation of the gene
is controlled by multiple feedback pathways. The expression of genes can be considered
similar to turning a switch ON or OFF within an electrical circuit [1]. From a systems
viewpoint, the living cell is like a multi-input- multi-output (MIMO) feedback system. It
is the ON and OFF mechanisms of the genes, along with their feedback signaling that
help the systems achieve homeostasis. Understanding such a system is the most important
challenge in systems biology.
1.6 Dynamical Systems Modeling
An important aspect of modeling is to understand the dynamics of the gene regulatory
network. Due to the associated complexities of these gene regulatory networks, intu-
ition alone will not present a complete understanding of the system. Instead, an explicit
mathematical description of the network is required that will explain the system dynamics
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completely. A dynamical system is a system whose time evolution of states are defined
by mathematical equation. This equation tells us how the system is going to be changing
its state from one time point to another. A simple example of a dynamical system is an
oscillating simple pendulum. The state along with the equations will define the system
completely. The mathematical equations essentially define the model of the system.
The defined model can be a continuous or discrete state system. A continuous system
is the one where the value of state variables vary as a real number. Discrete systems are
the ones where the state variables can take only certain predefined discrete values. Addi-
tionally, the mathematical equations describing the state transitions can be deterministic
or stochastic. The biological system is one such dynamical system whose state changes
depending on the intra- and extra-cellular signals it receives. As explained previously,
a gene can be turned ON or OFF. Though a gene is being expressed when it is turned
ON the amount of protein produced depends on the requirements of the cell. Thus, it is
a continuous variable and changes its values depending on the demands. However, bio-
logical systems’ response usually occurs beyond a certain threshold, in the sense that the
quantity of the protein determines its activity. Thus protein activity exhibits a switch like
behavior [1]. The biological system can thus be modeled as a continuous or a discrete sys-
tem. So the choice of the type of modeling to use will depend upon other considerations.
The continuous time models, using differential equations, provide a more detailed picture
of network dynamics, but the number of parameters required apriori is too large, too ex-
pensive and usually unavailable. An alternative to this is the use of discrete logic-based
models that can provide a good qualitative approximation of the system. The reason for
preferring this alternative is that biologists find it easier and more intuitive to describe gene
expression in terms of discrete states-ON/OFF. In this dissertation, the biological systems
under consideration have all been modeled as discrete-state and discrete-time systems, but
both deterministic and stochastic transitions have been considered.
12
1.7 Research Plan
1.7.1 Modeling Stress Response Pathways
1.7.1.1 Related Works
The gene regulatory relationships considered in these models are deterministic in na-
ture. The p53-Mdm2 gene regulatory network in a deterministic sense was modeled in [2].
Based on the Boolean model thus developed, the authors studied the dynamics of such a
system and compared it with available evidence in literature to evaluate the performance.
1.7.1.2 Modeling Oxidative Stress Response Pathways
The significance of oxidative stress response pathways in the human body is discussed.
These pathways are modeled as boolean networks and algorithms implemented for under-
standing the dynamics of the system. The results from simulations are compared with
literature evidence to evaluate performance. The model considered is discrete state deter-
ministic model.
1.7.1.3 Modeling Hypoxia Stress Response Pathways
The hypoxia stress response pathways and their relevance to cancer are discussed.
These pathways are modeled as boolean networks and algorithms are implemented for
understanding the dynamics of the system. The model considered is a discrete state deter-
ministic model.
1.7.2 Fault Detection and Control in Stress Response Pathways: A Deterministic
Approach
1.7.2.1 Related Works
As mentioned earlier, the ultimate aim of the modeling and dynamical systems ap-
proach is to locate faults in the system and to successfully intervene to correct for their
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harmful effects. In [3], growth factor pathways were modeled and drug intervention strate-
gies designed for different pathway mutations. In this dissertation, this work has been im-
proved upon by considering some more factors to make the problem more realistic. The
pathways considered in [3] are acyclical in nature, that is, they contain no feedback loops.
However, we consider cyclical networks which have feedbacks.
1.7.2.2 Detection of Multiple Faults in a Cyclic Gene Regulatory Network
In [3], the network considered did not have any feedback loops. It is more realistic
when the considered network has feedback loops in them. For solving this problem, ox-
idative stress response pathways along with PI3K/Akt pathways are considered. Input to
the system are designed such that they are capable of detecting faults (mutations) in the
system based on the signature of output downstream genes.
1.7.2.3 Drug Intervention in a Cyclic Gene Regulatory Network
In [3], due to the absence of feedback loops, the state of the system is static after
a few time-steps. In order to consider feedback connections, the hypoxia stress response
pathways modeled earlier were augmented with other pathways that play an important role
in cancer. In this case due to feedback connections the state of the system is oscillatory.
Drug intervention strategies were designed by considering the major pathways influenced
by hypoxia.
1.7.3 Control in Signaling Pathways Under Uncertainty: A Stochastic Approach
1.7.3.1 Related Works
The previous methods assumed that the transitions between states happens in a deter-
ministic manner. It is known that biological systems do not behave that way and there is
some amount of stochasticity to transitions at every time-step. Perfect knowledge of un-
derlying transition probabilities between states is necessary to design an optimal control
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action. We are interested in modeling a Gene Regulatory Network (GRN) as a Markov De-
cision Process (MDP). The theory for analysis and control of MDP is very rich. The reader
is referred to [4] for a detailed discussion on this topic. In biological systems very little
is known about the true dynamics of the system due to the paucity of available data and
the costly experiments involved for generating such data. Additionally, variation across
biological systems is too confounding to come up with these transition probabilities. To
address this uncertainty, one can construct an uncertainty class of models and optimize an
objective function across the entire uncertainty class. Previously, biological systems were
modeled as Boolean Networks (BN) and its probabilistic variant Probabilistic Boolean
Network (PBN) and intervention techniques designed for such systems [5–10]. In these
models it was assumed that the information about the transition probabilities in the system
is known or can be generated with some uncertainty about them. To refine these models,
prior knowledge in the form of pathways which gives the relational regulation between
a pair of genes/proteins was considered [3]. However, the models were deterministic in
nature. Furthermore, in these models the mutations were identified and corrective interven-
tions designed based on the signature of chosen downstream genes. This prior knowledge
is however, partial and incomplete. Yousefi et. al [11] extended the work by assuming
a probability distribution over the state transition probabilities. The probabilities were
updated under a Bayesian framework based on data from the system to reduce the uncer-
tainty. The intervention (control) problem was formulated and solved as an optimization
problem in the dynamic programming framework.
1.7.3.2 Uncertainty in Stochastic Dynamical System: Bayesian Control
In this current work, prior biological knowledge is incorporated in the form of path-
way information. Since there is some uncertainty in the regulation of the pathways, a prior
probability distribution is defined over each pathway. The parameters of the distribution,
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which determine its shape express the degree of confidence in this prior knowledge. Such
information expressed over the pathways is used to generate the Transition Probability
Matrix, T PM, which defines the complete dynamics of the model. The observations from
the true system are used to update and reduce uncertainties in the designed model. An
optimization framework is defined to estimate an optimal intervention action. This action
is optimal for the model determined by the prior defined over the system. The objective
function for the optimization problem is the expected cost relative to the probability dis-
tribution over the uncertainty class and an optimal Bayesian robust intervention policy
minimizing this cost function is formulated.
1.7.3.3 Computational Issues: Q-Learning
In [11], the intervention (control) problem was solved under a dynamic programming
framework, this however, was computationally intensive and non-tractable for network
sizes of a few nodes. Hence , it was not possible to extend these methods to larger prac-
tical sized networks. To alleviate this issue, sub-optimal solutions are formulated using
the framework of Q-learning. It was seen that not only was there a significant gain in
computational issues, but the costs derived in both the methods were comparable to each
other.
1.8 Dissertation Outline
The dissertation is organized as follows:
• Section 2: General structure of stress response pathways are introduced. Oxidative
stress response pathways are discussed. These pathways are modeled as boolean
networks and algorithms implemented for locating the faults (mutations) in the net-
work based on signature of specific genes. The model considered is discrete time
deterministic model.
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• Section 3: Hypoxia stress response pathways and its relevance in cancer are dis-
cussed. These pathways are modeled as boolean networks and algorithms imple-
mented for designing combination drug therapy which will be more effective than
treating with a single drug. The model considered is discrete time deterministic
model.
• Section 4: Uncertainties in pathways are expressed as a distribution and an uncer-
tainty class representing the system derived. Based on observations from the true
system the size of the uncertainty class was reduced using an bayesian update frame-
work. A control scheme was also designed which was adaptive and non-stationary
in nature.
• Section 5: Some conclusions and future research directions are outlined.
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2. OXIDATIVE STRESS RESPONSE PATHWAYS *
2.1 Introduction
The control of gene expression in eukaryotic organisms is achieved via multivariate
interactions between different biological molecules such as proteins and DNA [12]. Con-
sequently, in recent years, various genetic regulatory network modeling approaches such
as differential equations and their discrete-time counterparts, Bayesian networks, Boolean
networks (BNs) and their probabilistic generalizations, the so-called probabilistic Boolean
networks (PBNs) [13] have been proposed for capturing the holistic behavior of the rel-
evant genes. Some of these approaches such as differential equations involve finer mod-
els and require a lot of data for inference while others such as Boolean networks yield
coarse models with lower data requirements for model inference. On the other hand,
historically biologists have focused on experimentally establishing marginal cause-effect
relationships between different pairs of genes, which when concatenated together leads
to what is known as pathway information. Biological pathways are used by biologists to
represent complex interactions occurring at the molecular level inside living cells [14].
Pathway diagrams describe how the biological molecules interact to achieve their biologi-
cal function in the presence of appropriate stimuli [15]. At a very simple level, biological
pathways represent the graphical interactions between different molecules. However, as
already noted, the pathways give only a marginal picture of the regulations (up-regulation
or down-regulation) of the different genes/RNAs/proteins by other genes/RNAs/proteins.
The complexity of biological signaling and the prevelance of prior information in the
form of pathway knowledge demand that genetic regulatory network models consistent
*This section is reprinted with permission from “Boolean modeling and fault diagnosis in oxidative stress
response” by S Sridharan, R Layek, A Datta and J Venkatraj, BMC Genomics 2012, 13(Suppl 6):S4.
doi:10.1186/1471-2164-13-S6-S4.
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with pathway information be developed. Motivated by this, we developed an approach
to generate Boolean network models consistent with given pathway information and ap-
plied it to studying the p53-mediated DNA damage stress response [2]. In addition, we
used a signaling diagram of the MAP-Kinase pathways to predict possible location(s) of
the single signaling breakdowns, based on the cancer-causing breakdown signature [3].
Moreover, we also made theoretical predictions of the efficacy of different combination
therapies involving six anti-cancer drugs, which we plan to validate in the near future.
In this work, we first develop a Boolean network model consistent with oxidative
stress response pathway information from the biological literature. Thereafter this model
is linked with the PI3k/Akt pathway and the composite model is used to pinpoint the
possible fault locations based on the observed deviations in the apoptotic signature over
different time windows. This section is organized as follows. Section 2.2 contains a brief
general description of Stress Response Pathways while Section 2.3 presents a discussion
specific to the case of oxidative stress. The Boolean network model for oxidative stress
response is developed in Section 2.4. The role of mitochondria as the site in a cell where
the oxidative stress is generated is discussed in Section 2.5. In Section 2.6, we develop an
integrated network linking oxidative stress response to the phenomenon of apoptosis via
the PI3k/Akt pathways. Section 2.7 presents an approach for pinpointing fault locations
in the integrated network by observing the apoptotic signature in response to certain test
stress input sequences. Finally, Section 3.9 contains some concluding remarks.
2.2 Stress Response Pathways
Adaptive stress response pathways are the first responders to chemical toxicity, radi-
ation, and physical insults. The different stress response pathways share a very similar
architecture. This architecture has three main components: a transducer, a sensor and a
transcription factor (TF) [16]. The transcription factor (TF) is a DNA-binding protein that
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Figure 2.1: General scheme of stress response pathways
interacts with the promoter regions of its target genes via its canonical DNA-binding sites,
known as ‘response elements’ (REs), to activate the expression of the target genes. The
sensor is a protein that physically interacts with the transcription factor in the cytosol, se-
questering the transcription factor from the nucleus under normal cellular conditions. In
addition to its role in cytoplasmic sequestration of the TF, the sensor may direct TF degra-
dation, providing an additional layer of regulatory control. The result of the sensor-TF
complexation is to maintain inactivity of the TF under normal cellular conditions, while
providing a mechanism that permits activation in response to an appropriate insult to the
cell. The transducer is an enzymatic protein, such as a kinase, that conveys a biochemi-
cal change from a signaling pathway upstream of the sensor/TF complex in the event of
cellular stress. The transducer may directly modify the transcription factor, providing the
activating signal or modify the sensor which in turn, destabilizes the sensor/TF complex.
Liberated, stabilized, and activated, the transcription factor relocates to the nucleus where
it activates its target genes. Generally the sensor and TF are unique for a given stress re-
sponse pathway unlike transducers which can be shared between different stress response
pathways, leading to what is commonly referred to as ‘cross-talk’ between the pathways.
A schematic diagram showing the general architecture of a stress response pathway is
shown in Fig. 2.1.
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2.3 Oxidative Stress Response Pathways
Oxidative stress is caused by exposure to reactive oxygen intermediaries/species (ROS).
The stress induced on the cells by electrophiles and oxidants gives rise to a variety of
chronic diseases. The outcome of interactions between the cell and oxidants is deter-
mined largely by the balance between the enzymes that activate the reactive intermediaries
and the enzymes that detoxify these reactive intermediaries [17]. For example, oxidative
stress contributes to aging and age-related diseases such as cancer, cardiovascular disease,
chronic inflammation, and neurodegenerative disorders. The body has developed a variety
of counteractive measures for combating oxidative stress. At elevated concentrations of
electrophiles the complex Keap1-Nr f 2 (made up of the transcription factor Nr f 2 and sen-
sor Keap1) is broken and Nr f 2 is liberated and transported into the nucleus. Keap1 has
been known to sequester Nr f 2 in the cytoplasm and also leads to the proteasomal degra-
dation of Nr f 2. Once the complex is broken, Nr f 2 is phosphorylated and transported to
the nucleus. Inside the nucleus, Nr f 2 forms heterodimers with small Maf proteins (SMP)
which then binds to the anti-oxidant response element (ARE) and leads to the translation
of antioxidant genes, which produces Phase II detoxifying enzymes. The purpose of this
is to detoxify the electrophiles to water soluble components. Thus in response to elevated
concentrations of electrophiles, various antioxidant proteins are activated [18–22]. The
schematic diagram for Nr f 2 activation is shown in Fig. 2.2. In the rest of this section,
the term ARE will be interchangeably used to represent either the antioxidant response
element cis enhancer sequence that is upstream of the gene promoters for the antioxi-
dant proteins or the antioxidant genes/proteins themselves. The context will make it clear
whether we are referring to the regulatory sequence or to the resulting gene/protein.
We next focus on the procedure by which Nr f 2 is deactivated. This is carried out by
other proteins that stop translation of the antioxidant genes once the electrophiles have
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Figure 2.2: Nrf2 activation
been neutralized. For instance, the Bach1-SMP complex has been known to bind to the
same region on the ARE as the Nr f 2-SMP complex. Similarly, small Maf proteins are
known to form homodimers or heterodimers with other small Maf proteins. These protein
complexes are known to bind to the same location on the ARE as the Nr f 2-SMP complex.
So, once the electrophiles have been eliminated, these protein complexes bind to the ARE
and displace Nr f 2 which is then transported back to the cytoplasm. In the cytoplasm,
it binds with Keap1, which directs its proteosomal degradation [23–26]. The schematic
diagram for Nr f 2 deactivation is shown in Fig. 2.3.
One of the byproducts of normal metabolism is the production of a large number of free
radicals. Oxidative stress is caused by the production of free radicals in quantities beyond
those that can be handled by the cellular antioxidant system. Indeed, oxidative stress has
been implicated in the development of many age-related diseases, including neurodegen-
22
Cytoplasm
Nucleus
Nrf2 Proteosomal Degradation
(b)
Keap1 Nrf2
Nrf2
P Bach1
Small 
Maf 
Proteins
Antioxidant Response Element
Figure 2.3: Nrf2 deactivation
erative ones, such as Alzheimer’s and Parkinson’s, and in aging itself. In addition, excess
free radicals react with the nucleotides in the DNA resulting in mutations in the long run.
Although there are cellular mechanisms to sense and repair the oxidative DNA damage,
mutations can accumulate over a period of time and result in a major disease like cancer.
In the next section, we develop a Boolean network model for oxidative stress response
pathways. This network will be later utilized to analyze different failure modes that can
suppress apoptosis and possibly lead to cancer.
2.4 Boolean Network Modeling of Oxidative Stress Response Pathways
Before proceeding to the actual modeling of the specific oxidative stress response path-
ways, we first formally define the general terms ‘pathway’ and ‘Boolean Network’ follow-
ing the detailed development in [2]. Given two genes/proteins A and B and binary values
a,b ∈ {0,1}, we define the term pathway segment A t:a,b−→ B to mean that if gene/protein
A assumes the value a then gene/protein B transitions to b in no more than t subsequent
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time steps. A pathway is defined to be a sequence of pathway segments of the form
A
t1:a,b−→ B t2:b,c−→C.
A Boolean Network (BN), ϒ = (V,F), on n genes is defined by a set of nodes/genes
V = {x1, ...,xn}, xi ∈ {0,1}, i = 1, ...,n, and a list F = ( f1, ..., fn), of Boolean functions,
fi : {0,1}n → {0,1}, i = 1, ...,n [1]. The expression of each gene is quantized to two
levels, and each node xi represents the state/expression of the gene i, where xi = 0 means
that gene i is OFF and xi = 1 means that gene i is ON. The function fi is called the predictor
function for gene i. Updating the states of all genes in ϒ is done synchronously at every
time step according to their predictor functions. At time t, the network state is given by
x(t) = (x1(t),x2(t), ...,xn(t)), which is also called the gene activity profile (GAP) of the
network.
The modeling approach that we will follow here involves using the biological pathway
knowledge from the literature and applying Karnaugh map reduction techniques to it to
obtain an update equation for each node of the Boolean network [2]. The details specific to
the oxidative stress response pathway are discussed next. The pathway segments relevant
to the oxidative stress response are given below [18, 19, 21, 24, 27, 28]:
ROS
1:1,0−→ Keap1 (2.1)
ROS
1:1,1−→ PKC (2.2)
ROS
1:a,a¯−→ Bach1 (2.3)
Keap1
1:b,b¯−→ Nr f 2 (2.4)
Nr f 2,ROS
1:(1,0),1−→ Keap1 (2.5)
PKC
1:1,1−→ Nr f 2 (2.6)
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Figure 2.4: Oxidative stress response pathways
Bach1,SMP
1:(1,1),0−→ ARE (2.7)
Nr f 2,SMP
1:(1,1),1−→ ARE (2.8)
SMP,SMP
1:(1,1),0−→ ARE (2.9)
ARE
1:1,1−→ SMP (2.10)
ARE
1:1,0−→ ROS (2.11)
ARE
1:1,0−→ PKC (2.12)
In these pathways ARE represents the family of antioxidant genes in the sense that if
the correct complexes bind to ARE it leads to the up-regulation/down-regulation of the
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Figure 2.5: Karnaugh maps for deriving the Boolean network of oxidative stress response
pathways
appropriate antioxidant gene. These pathway interactions are pictorially represented in
Fig. 2.4. In this figure we have used square boxes without making any distinction between
whether they represent proteins/genes or a biochemical entity. ROS stands for reactive
oxidative species which is a biochemical entity. The other entities like PKC, Keap1,
Nr f 2, Bach1 are all proteins and ARE (Antioxidant Response Element) is a cis enhancer
sequence that is upstream of the gene promoters for the antioxidant proteins or the antiox-
idant genes/proteins themselves. Also the merged activation (Nr f 2/SMP) or inhibition
(Bach1/SMP) corresponds to dimers formed between these components. The Karnaugh-
maps for the genes/proteins are shown in Fig. 2.5.
From the pathways described above and using the Karnaugh-map reduction techniques,
the Boolean update equations for each node of the network are deduced. Some logical rea-
26
soning has been used for determining the equations: 1) the maximum number of predictors
for updating a variable is fixed to be 3; 2) Small Maf Protein is assumed to be ubiquitously
expressed and the pathway given by Eqn.(2.10) only increases the concentration of SMP,
which in conjunction with Eqn.(2.9), binds to ARE and down-regulates the antioxidant
gene; 3) a gene being turned on implies that the corresponding protein is being produced
although, in reality, this is not necessarily true; and 4) in the case of a conflict in the
Karnaugh map, biological knowledge has been used to assign either a 0 or a 1. This last
point is demonstrated by a specific example. For instance, in the case of ARE, the entry
shown with a grey circle around it says that when both Bach1 and Nr f 2 are upregulated
and antioxidant gene is downregulated, then at the next time step antioxidant gene will be
upregulated. The biological explanation for such an update is that it corresponds to the
situation where, in the presence of Stress, Nr f 2 has been activated and is relocating to
the nucleus while the inhibitor Bach1 is simultaneously relocating to the cytoplasm prior
to the activation of antioxidant gene at the next time step. Such intuitive reasoning has
been used to model the system here. One might use a different reasoning which could lead
to a different set of update equations. However, since we are concerned only about the
final steady-state behavior, such reasoning can be justified as long as the overall system
behavior, defined by the update equations, matches the steady-state. As an example, the
final update equation for ARE is derived as follows. In the K-maps, the ones are grouped
up in pairs of 2,4,8 and so on and each group should have at least one variable staying con-
stant. So for this case there are two groups whose equations correspond to Nr f 2 · (ARE)
and Nr f 2 · (Bach1). The final update equation for ARE is the sum of these two equations.
Indeed, by working with different sets of update equations, we determined that all biolog-
ically plausible ones led to the same/similar attractor behavior. From the set of possible
Boolean networks we chose the ones that appealed most to our biological understanding
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and the resulting update equations are given below:
ROSnext = Stress ·ARE (2.13)
Keap1next = ROS · (Nr f 2+Keap1) (2.14)
PKCnext = ROS ·ARE (2.15)
Nr f 2next = PKC+Keap1 (2.16)
Bach1next = ROS (2.17)
SMPnext = 1 (2.18)
AREnext = Nr f 2 · (ARE +Bach1). (2.19)
An equivalent digital circuit with logic gates is shown in Fig. 2.6. Here the lines in bold
represent feedback paths. The state transition diagrams resulting from Eqns. (2.13)-(2.19)
for the two cases Stress=0 and Stress=1 are shown in Figs. 2.7 and 2.8 respectively.
In these transition diagrams, the genes in the binary state representation are ordered as
[ROS Keap1 PKC Nr f 2 Bach1 ARE] and the binary states are compactly represented by
their decimal equivalents. For instance, the binary state (111100) would be represented
by the decimal number 60. The states of particular interest are the attractors as they give
rise to the steady-state properties of the network. In Fig. 2.7 , the state of interest is the
singleton attractor 18(010010). On the other hand, in Fig. 2.8 , the states of interest are
the seven states forming the attractor cycle. These states are: 18(010010), 50(110010),
40(101000), 44(101100), 45(001101), 5(000101) and 23(010111) traversed in that order.
They would lead to cyclical/oscillatory behavior in the time domain response.
It is clear from the preceding discussion that some kind of oscillatory behavior of the
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Figure 2.6: Equivalent Boolean network for oxidative stress response
genes will be observed when the external Stress input equals 1. On the other hand, when
the Stress input equals 0, the system will rest in only one state meaning that there will be
no oscillation.
2.4.1 Time Domain Simulation Results
The network obtained was simulated using MATLAB by giving an external stress input
signal for a duration of 50 timesteps, and both the input signal and the responses are shown
in Fig. 2.9. The signal ROS is a biological manifestation of the external input signal, Stress
being applied to the network. The biological purpose of this network is to counteract the
effect of ROS produced in response to the Stress input. As we can see from Fig. 2.9 , in
the absence of any Stress signal, the system reaches the singleton attractor 18(010010).
Once Stress signals are applied, there are oscillations as theoretically expected from the
existence of an attractor cycle. In Reichard et al. [23], the cells were treated with Arsenite,
a well known activator of Nr f 2 and an out-of-phase relationship was observed between
Nr f 2 and Bach1. Shan et al. [26] also showed a similar out of phase relationship. In
Katsuoka et al. [25] DEM (an activator of Nr f 2) also leads to increased expression of
NQO1 which is a known anti-oxidant response element. Such an in-phase relationship
between Nr f 2 and the antioxidant gene is also seen in Fig. 2.9. Thus the theoretical
predictions made by our Boolean network model for oxidative stress response appear to
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Figure 2.9: Time response behavior of the system in Fig. 2.4
be consistent with experimental observations from the published literature. Note, however,
that these experiments consider only two genes/proteins at a time and therefore, there is a
need for experimentally studying the simultaneous activities of ROS, Keap1, Nr f 2, PKC,
Bach1 and ARE in the time domain.
2.5 Mitochondria and Free Radical Generation
Mitochondria play an important role in cellular energy metabolism, free radical gener-
ation and apoptosis. It has long been suspected that mitochondrial functions contribute to
the development and progression of cancer [29–31]. Over 70 years ago, Otto Warburg pro-
posed that a key event in carcinogenesis is a defect in the respiratory mechanism, leading
to increased glycolysis even in the presence of oxygen;this is known as the Warburg ef-
fect [32]. The well known function of mitochondria is to generate Adenosine Triphosphate
(AT P) molecules providing energy for the survival of the cell through oxidative phospho-
rylation (OXPHOS), which is collectively accomplished by proteins encoded both by nu-
clear and mitochondrial DNA. Oxidative phosphorylation is a metabolic process, which
takes place in mitochondria in which AT P is formed as a result of the transfer of elec-
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Figure 2.10: Stages of oxidative phosphorylation producing free radicals
trons from NADH or FADH2 to O2 by a series of electron carriers. OXPHOS is the major
source of AT P as well as free radical generation in aerobic organisms. For example, ox-
idative phosphorylation generates 26 of the 30 molecules of AT P that are formed when
a molecule of glucose is completely oxidized to CO2 and H2O, although 1 to 2% of the
electrons are lost during transfer through the chains leading to free radical generation [33].
Fig. 2.10 [34]shows a schematic representation of the whole process along with free rad-
ical generation. The points shown with red stars correspond to the locations where free
radicals are generated.
Even though it has been long recognized that increased ROS production in mitochon-
dria leads to genetic instability and progression of cancer, there remain several unanswered
questions regarding the complex signaling capacity of this organelle [35]. The DNA is
highly susceptible to free radical attacks. Free radicals can break DNA strands or delete
bases. These mutations can prove to be carcinogenic. It has been estimated that more
than 10,000 hits of oxidative stress occur each day. So it is important to tackle these free
radicals at the source of their generation, which is why the mitochondria is also a very
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rich source of anti-oxidants. Although cellular mechanisms can tackle this stress, dam-
age accumulates with age. At present altered energy metabolism is considered to be an
additional hall mark of cancer progression [36] and these metabolic pathways have been
investigated as targets for cancer therapy. In this work, we will specifically focus on the
PI3k/Akt pathway which is one such pathway and is described in the following section.
2.6 An Integrated Network for Oxidative Stress Response and Apoptosis
Cancer is an umbrella term for diseases that are associated with loss of cell-cycle con-
trol, leading to uncontrolled cell proliferation and/or reduced apoptosis. It is often caused
by genetic alterations leading to malfunctioning in the biological pathways [12, 37, 38].
One of the possible cellular responses resulting from oxidative stress is the induction of
apoptosis. Thus it is important to develop a network model linking the oxidative stress
input to the fate of the cell. In this section, we will do precisely that by considering the
oxidative stress response pathways alongside other downstream pathways capable of in-
ducing apoptosis. Specifically, we will focus on the PI3k/Akt pathway. The PI3k/Akt
pathway is downstream of the Ras gene which is known to play an important role in many
cancers. In addition, other genes in the PI3k/Akt pathways are found mutated in many
cases of cancer. Oxidative stress often upregulates many of the genes in the PI3k/Akt
pathway. The detailed interactions between the oxidative stress response pathway and the
PI3k/Akt pathway are shown in Fig. 2.11 [12,39–41]. Starting with this pathway diagram
and utilizing the procedure developed earlier in section 2.4, an equivalent digital circuit
in terms of logic gates can be implemented as shown in Fig. 2.12. The above circuit is
modeled with two output genes which effectively control the final fate of the cell. Bad and
Bcl2 are known to have pro-apoptotic and anti-apoptotic functions respectively and thus
can serve as biomarkers of apoptosis induction. Indeed, it is the delicate balance between
the activity of these two genes that dictates the ultimate fate of the cell [42–44]. The pur-
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pose of the Nr f 2-ARE pathway in this integrated network is to reduce the average value
of ROS present in the system, in response to the oxidative stress. This is clear from the
plot in Fig. 2.9 : between the time instants from the 25th timestep to the 75th timestep
when there is a continuous Stress present in the system, the ROS present in the system is
oscillating between 0 and 1 which implies that its average value is less than ’1’, which is
the value that we would have otherwise had in the absence of the Nr f 2-ARE pathway.
2.7 Classification of Faults in the Integrated Network
In the integrated pathway diagram of Fig. 2.11 , the two genes namely Bad and Bcl2 are
instrumental in deciding the fate of the cell. The preferred status of the two genes, when
oxidative stress is not being neutralized, are 1 and 0 respectively since it corresponds to
the situation where the pro-apoptotic factor is turned ON and the anti-apoptotic factor is
turned OFF. Although a deviation from this state may not signal that the cell is turning
cancerous, there is a higher possibility of the cell exhibiting aberrant behavior.
Depending on the final resting status of these two genes, one may be able to character-
ize the degree of invasiveness of the disease especially if it is being caused by apoptosis
suppression. Once it has been determined that a cell is exhibiting aberrant behavior, one
would like to pinpoint the location of the fault/error so that the necessary therapeutic in-
tervention(s) can be applied. Since the digital circuit model of Fig. 2.12 uses logic gates,
it should be possible to use the fault detection techniques from the Digital Logic litera-
ture [45, 46] to pinpoint the fault locations. This will be carried out in this section. An
important difference between the results obtained in Layek et al. [3] for pinpointing the
fault locations in the MAPKinase pathways and the results to be presented here is that the
digital circuit in Fig. 2.12 involves feedback and its behaviour is, therefore, much more
complicated to analyze. However, it should be pointed out that the simpler fault pin-
pointing methodology presented in Layek et al. [3] is much more amenable to biological
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validation via appropriately designed experiments while the same cannot be said about
the results to be presented here. Indeed, the results to be presented here show that the
pinpointing of the fault locations is theoretically possible even in this case, although the
biological feasibility of the methods required is open to question.
We note that the faults in a digital circuit are mainly of two types [45]:
• Stuck-at Faults: As the name implies, this is a fault where a particular line l is stuck
at a particular value α ∈{0,1}, denoted by line l,s-a-α (s-a-α means stuck-at-α).
This means that the value at that line is always going to be α regardless of the inputs
coming in. This can be thought of as something similar to a mutation in a gene,
where a particular gene is either permanently turned ON or OFF.
• Bridging Faults : This is the type of fault where new interconnections are introduced
among elements of the network. This can be thought of as new pathways being
created in the cell. This type of fault is not considered in the current work due to the
lack of biological knowledge about new pathways being introduced.
Here, it is appropriate to mention that the biological relevance of each of these two types
of faults has been discussed in Layek et al. [3].
The digital circuit in Fig. 2.12 has feedback (shown in bold lines) and is, therefore, a
sequential circuit. To detect a fault in a sequential circuit we need a test sequence. Let
T be a test sequence and let R(q,T ) be the response of the fault-free sequential system N
starting in the intial state q. Now let the faulty sequential circuit be denoted by N f where
f is the fault. Let us denote by R f (q f ,T ) the response of N f to T starting in the intial state
q f . A test sequence T detects a fault f iff (if and only if or equivalently this condition is
both necessary and sufficient) for every possible pair of intial states q and q f , the output
sequences R(q,T ) and R f (q f ,T ) are different for some specified vector ti ∈ T . The output
being observed is the status of [Bad,Bcl2].
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Once this output shows a deviation from a desired value, it becomes imperative to
pinpoint the possible fault locations which can give rise to the aberrant behaviour. To
do so, one can represent the digital circuit of Fig. 2.12 as in Fig. 2.13. The Primary
Input(PI) is Stress which is the only external signal which the experimenter has control
over. The Primary Output’s (PO’s) are the status of Bad and Bcl2, which are the only
outputs available to the experimenter. The Secondary Output’s and Secondary Input’s
are [ARE,Keap1,Mdm2], which are being fed back into the system. The states of these 3
genes ARE, Keap1 and Mdm2 determine the internal state of the system. These 3 elements
can be considered as memory elements of the system as their previous state is retained by
the system and fed back. The input sequence consists of two parts namely a Homing
sequence and a Test sequence, denoted by H and T respectively.
The purpose of this procedure is to pinpoint the possible locations for the fault f in N f ,
given the output sequence of Bad and Bcl2 for the normal and faulty circuits. It is assumed
that we have no knowledge about the initial status of any of the genes. Knowledge of the
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Figure 2.13: Block diagram representation of Fig. 2.12
initial status of the internal states is important as all future computations are based on
these values. The Homing sequence is an initial input sequence that brings the network
to a known internal state. So, once the Homing Sequence is given to N and N f , N will
come to a known internal state. Note that a similar claim cannot be made about N f as the
fault f is not known apriori. For the circuit in Fig. 2.12 , a possible Homing sequence is
[0 0 0 0 0 0 0 0], which brings the internal state of the system to [0 1 0]. This means that
if the Stress input is zero for eight time steps, then at the end of that period, the internal
state of the system becomes [0 1 0], regardless of the initial status of any of the genes in
the network. A reason for choosing this Homing sequence is that it implies that no input
needs to be given to the system and it evolves to the indicated internal state. In future
when we are trying to validate these results experimentally this will be of immense help.
If we refer back to Fig. 2.7, we see that regardless of the intial state, within four time steps
the trajectory reaches the state (’010010’) where ARE=0 and Keap1=1. This is consistent
with the conclusion that we are getting from the Homing sequence here with the only
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Figure 2.14: Fault detection using time-frame expansion
difference that a slightly longer sequence is required here as the state transition diagram
has a higher cardinality than that in Fig. 2.7.
Once the Homing sequence has done its job, the Test sequence(T ) is fed into N and
N f , and by comparing the output states of the normal and faulty networks, we can pinpoint
the location of the fault in the network, assuming that a single stuck-at-fault has occurred.
This can be carried out using the time-frame expansion method which is briefly discussed
next. The block in Fig. 2.13 is replicated n times with the feedback loops cut-off. The
Secondary Output of the kth stage is fed as the Secondary Input for the (k+ 1)th stage.
The Primary Outputs of the first (n−1) stages are neglected. The Primary Outputs of the
nth stage of the normal and faulty circuits will be different as the network configurations
are different for both. The Primary Input sequence has to be derived so that the error in a
line is propagated to the primary output in n time steps, so that a difference is observed at
the primary outputs of the normal and faulty circuits [45, 46]. The situation is pictorially
represented in Fig. 2.14. Please refer to Appendix A for a simple example that explains
the method.
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Test Sequence Faults Detected 
 s-a-0 s-a-1 
10100000 Ras, PI3K, PIP2, PIP3, Akt, Keap1 
PIP3,  Akt, Ras, PI3K, PIP2, PTEN, ARE, PKC, 
ATM, p53 
110101000 
PTEN, Nrf2, ATM, Bach1, GSK-3 , 
p53 
Mdm2 
1011111100 Nrf2, ARE Bach1, Keap1 
11010010101000 Mdm2  
11110001010000  GSK-3  
Undetectable PKC  
 
Figure 2.15: Test sequences for detecting single stuck-at-faults.
From the preceding discussion in this section, we know that there are 15 possible
genes (this is the total number of genes in Fig. 2.11 , excluding the output genes Bad and
Bcl2) where there could be a mutation. This means that there are 30 cases of faults as
a single gene can be mutated as a s-a-0 or as a s-a-1. We consider all possible cases of
single mutation, because in the presence of mutation, the normal and faulty system cannot
produce the same output unless, of course, the mutated gene is not a critical one. Based on
the methods described earlier in this section, we came up with a list of test sequences for
the detection of each gene fault. It is to be noted that the Test Sequences generated here
are only for the Homing Sequence considered earlier. For a different Homing Sequence
the Test Sequence will also be different. The different test sequences and their ability to
detect different single stuck-at faults are tabulated in Fig. 2.15. Here, truncated versions
of the same test sequence can be used to detect different faults appearing in the same row.
For detecting any particular fault, one would apply the test sequence from the same row
truncated at the bit whose color matches that of the particular fault. The mismatch between
the outputs of the normal and faulty systems, characterized by the vector [Bad,Bcl2]would
then result in the detection of that fault. Thus we have developed a method to pinpoint the
possible fault locations in a Boolean network with feedback. The algorithm will work with
multiple fault cases too with minor modifications.
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2.8 Concluding Remarks
In this section, we have developed a Boolean network model for the oxidative stress
response. This model was developed based on pathway information from the current lit-
erature pertaining to oxidative stress. Where applicable, the behaviour predicted by the
model is in agreement with experimental observations from the published literature. It is
our hope that some of the additional predictions here, such as those pertaining to the oscil-
latory behaviour of certain genes in the presence of oxidative stress, will be experimentally
validated in the near future.
We have also linked the oxidative stress response to the phenomenon of apoptosis
via the PI3k/Akt pathway. An integrated model based on collectively considering the
PI3k/Akt pathways and the oxidative stress response pathways was developed and then
used to pinpoint possible fault locations based on the Bad-Bcl2 apoptotic signatures in
response to ’test’ oxidative stress inputs. The approach used to achieve this differs signif-
icantly from the earlier results in Layek et al. [3] since the Boolean network considered
here has feedback. The approaches used here and in Layek et al. [3] could potentially have
a significant effect on cancer therapy in the future as pinpointing the possible fault loca-
tion(s) in cancer could permit the choice of the appropriate combination of drugs (such as
kinase inhibitors) for maximum therapeutic effectiveness. Of course, it should be pointed
out that the theoretical procedure presented here for pinpointing fault locations in a bi-
ological network with feedback will need to be further simplified before it can be even
considered for practical biological validation.
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3. HYPOXIA STRESS RESPONSE PATHWAYS *
3.1 Introduction
In this work, we develop a Boolean network model consistent with hypoxia stress re-
sponse pathway information from the biological literature. After this we consider the ma-
jor pathways involved in a hypoxic cell and consider targeted therapy in these pathways to
upregulate the average apoptotic activity and downregulate both the average cell-survival
activity and average energy production through fermentation. Misregulation of each of
these activities characterizes the difference between a normal cell and cancer cell. The ba-
sic underlying principles of modeling of this work is similar to the ideas used in modeling
the oxidative stress response pathways.
3.2 Hypoxia
Hypoxia is a condition in which there is an inadequate supply of oxygen to the tissues
of the body. If the oxygen entering inside a cell is not matching the oxygen demand of
the same cell, a hypoxic condition is created. Oxygen is rapidly taken up from the blood
into the tissues at the level of microcirculation, particularly from the capillaries. Oxygen
being highly lipid soluble, it passes through cell membranes. This rate of oxygen diffusion
is determined primarily by the PO2 (partial pressure of oxygen) , the pressure difference
between the plasma and cells surrounding the capillaries. The value of PO2 values is dif-
ferent among different capillaries, however the typical value ranges from 30-40 mmHg.
Since cells consume oxygen the PO2 inside cells is very low. This value drops to less than
1mm Hg (mercury) pressure inside the mitochondria where oxygen is used to generate
energy. With increased oxidative metabolism in a tissue, the mitochondria needs to make
*This section is reprinted with permission from “ Hypoxia Stress Response Pathways: Modeling and Targeted
Therapy” by S Sridharan, R Varghese, A Datta and J Venkatraj, accepted for publication in BMC Genomics
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more ATP and hence consume more oxygen. Though PO2 pressure difference drives the
diffusion process, an important factor in this is oxygen bound to haemoglobin. As and
when oxygen from plasma diffuses to the cells, the PO2 of plasma drops and this causes
oxygen bound to haemoglobin to become free. Therefore, the amount of oxygen bound to
hemoglobin is a major factor in determining oxygen delivery to a tissue. Hypoxic stress
is caused when the amount of oxygen available in a cell is insufficient to meet the energy
demands of that cell. In a living cell, this imbalance between oxygen supply and energy
demand arises due to physiological and pathophysiological processes [13]. A cell faces
hypoxic stress due to normal physiological variations during fetal development, wound
healing, adapting to a high altitude, inflammation etc. [47]. In a developing embryo, hy-
poxic stress is due to reduced oxygen supply, whereas while doing vigorous exercise, a
hypoxic condition is created in the exercising muscles due to an increased demand of
energy [48]. The optimum oxygen tension for tubulogenesis, vasculogenesis and angio-
genesis in an embryo of a mammal is about 23-38 mm Hg [47]. Different cells in the body
have different partial pressures of oxygen that are considered to be normal and a drop in
the partial pressure of oxygen below these normal levels, creates a hypoxic condition. The
difference of the partial pressures of oxygen between the blood and the mitochondria of the
cells is responsible for the transfer of oxygen between blood and all the cells in the body.
Hypoxia detection in human beings is carried out by the most vascular tissue in the human
body, the carotid body, which is located near the bifurcation of the carotid artery. The
partial pressures of inhaled air, arterial blood and venous blood are 150 mm Hg, 100 mm
Hg and 40 mm Hg respectively. The carotid body detects the gradient of the partial pres-
sure of oxygen of the arterial blood that flows through the carotid body. The intracellular
PO2 is regularly measured by three hydroxylases. These hydroxylases are named as prolyl
hydroxylase domain containing proteins (PHD), namely PHD1, PHD2, and PHD3 [47].
Almost 95% of the oxygen that we breathe in is used up by the reactions of the Electron
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Transport Chain (ETC), catalyzed by cytochrome oxidase, to produce energy. A proton
gradient is created across the innermost mitochondrial membrane as a result of some redox
reactions taking place in the mitochondrial ETC, due to the transfer of electrons from an
electron donor to the terminal electron acceptor, oxygen. This proton gradient is used to
phosphorylate ADP to form ATP in the presence of ATP synthase. The inhaled air, which
has a partial pressure of 150 mm Hg, passes into the alveoli which are the small air sacs
located inside the lungs. Oxygen mixes with the water vapor and carbon dioxide (exter-
nal respiration) and then enters into the arterial blood. Arterial blood carries oxygen to
the mitochondria in each and every cell of the body, where it extracts hydrogen from the
food to react with oxygen to produce water vapor. Carbon dioxide produced in the mito-
chondria enters into the venous blood and is expelled from the lungs. The normal partial
pressure of oxygen in the arterial blood is 100 mm Hg, and when it falls to 40 mm Hg, it
is very dangerous [49]. Oxygen consumption is thus coupled to release of energy in the
form of ATP, which is essential for the proper functioning of the cell. Hence, low oxygen
tension should be identified and proper adaptation measures should be taken by the cell
for survival. To harvest energy from food and to maintain the proper tissue function, an
adaptive response must be incorporated to overcome the scarcity of oxygen. The transcrip-
tion factor HIF (Hypoxia Inducible Factor) has a prominent role in the regulation of gene
expression levels by oxygen. HIF achieves this response by regulating the transcription of
thousands of hypoxia responsive genes. The interaction of HIF was identified for the first
time in erythropoietin (EPO) gene which is involved in angiogenesis [47].
3.3 Hypoxia Stress Response and Pathways: Hypoxia Inducible Factor (HIF) and its
Regulation
Hypoxia Inducible Factor (HIF) is a heterodimer comprising of α and β subunits.
HIFα consists of 3 subunits, HIF-1α , HIF-2α and HIF-3α .The HIFβ subunit consists of
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ARNT which is the aryl hydrocarbon nuclear translocator and ARNT2. HIF-1 transcrip-
tion factor consists of HIF-1α and HIF-1β (ARNT) [50]. The concentration of oxygen in
the cells regulates the HIF-1α subunit, but the HIF-1β subunit is unaffected by the oxy-
gen levels. HIF-1α quickly stabilizes and is accumulated under hypoxic conditions by
the inhibition of PHD2, but on re-oxygenation, it is suddenly destroyed and its half-life
is less than 5 minutes [51]. This short half-life shows that HIF-1α accumulation is not
good for the body. In fact, prolonged hypoxia is observed in most of the tumors. HIF-1α
also undergoes hydroxylation of the amino acid proline located in its oxygen dependent
degradation (ODD) domain by PHD2. HIF-1α undergoes hydroxylation of the asparagine
803 residue located in the C terminal activation domain (CTAD) by FIH (factor inhibit-
ing HIF) [52]. The hydroxylation of HIF-1α by PHD2 increases its interaction with the
tumor suppressor protein, pVHL, the von-Hippel Lindau tumor suppressor protein which
marks HIF-1α for degradation with the help of E3 ubiquitin ligase. PHD2 hydroxylates
HIF-1α and that creates a binding site for pVHL [53]. Again, the hydroxylation of HIF-
1α by FIH reduces the transcriptional activity of HIF-1α by preventing the binding of
coactivators p300/CBP to HIF-1α [54]. The hydroxylation of HIF-1α by FIH results in
p300/CBP independent transcription of HIF-1α . PHD and FIH require oxygen, iron, α-
ketoglutarate (αKG) and ascorbate as substrates to function properly. Oxygen and αKG
are the co-substrates required for PHD2 functioning whereas, ascorbate and Fe2+ (iron)
are the cofactors required for PHD2 functioning. PHD2 hydroxylates HIF-1α and simul-
taneously PHD2 decarboxylates αKG to succinate. αKG is an anion of α-ketoglutaric
acid which is produced by the deamination of glutamate (an intermediate of the citric acid
cycle) [55]. During hypoxia, the substrate oxygen required for PHD functioning is not
available and hence PHD is inhibited. This results in the activation and stabilization of
HIF-1α subunit which enters into the nucleus and binds with HIF-1β subunit to form the
HIF heterodimer [53, 54], which is a transcription factor. This HIF transcription factor
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binds to the Hypoxia Responsive Elements (HRE) of the target genes and this interaction
drives the transcription in a hypoxia responsive manner, up regulating the genes involved
in angiogenesis (EPO), vasculogenesis (VEGF), glycolysis (GLUT1, PDK1, LDHA), etc.
The Electron Transport Chain (ETC) directs the electron transport between the elec-
tron donors NADH (nicotinamide adenine dinucleotide) and FADH2 (flavin adenine din-
ucleotide) and the terminal electron acceptor oxygen. ETC takes place inside the mito-
chondria where O2 is reduced to H2O, NADH is oxidized to NAD+ and succinate in the
presence of the SDH (succinate dehydrogenase) enzyme is converted to fumarate. The
proton gradient generated across the mitochindrial membrane, pumps protons inside the
mitochondrial space which converts ADP (adenosine di phosphate) to ATP (adenosine tri
phosphateuses) using the enzyme ATP Synthase. This whole process is what is referred
to as oxidative phosphorylation. Some of the electrons will not be transferred from the
electron donor through the complexes I-IV to the terminal electron acceptor, and there
may be premature electron leakage through complexes I and III forming reactive oxygen
species (ROS) such as superoxide that creates oxidative stress [56]. During hypoxia, the
ETC is inhibited since there is not enough oxygen available, which generates even more
ROS thereby creating an oxidative stress [57]. This oxidative stress does not allow iron
to cycle between the different oxidation states which results in PHD inhibition since iron
is one of the cofactors required for PHD to function properly. PHD inhibition results
in the accumulation and stabilization of HIF-1α which results in the induction of anti-
apoptotic as well as apoptotic genes depending on the extent of hypoxia [58]. Activation
of the transcription factor HIF-1α results in a shift from aerobic metabolism to anaerobic
metabolism. Pyruvate kinase is a glycolytic enzyme that converts PEP (phosphoenolpyru-
vate) to pyruvate. PK-M2 (pyruvate kinase muscle isozyme 2) is one of the isozymes of
pyruvate kinase [59]. PHD3 hydrolyzes PK-M2 on proline-403/408, and the hydrolyzed
PK-M2 interacts directly with HIF-1α subunit which enhances the binding of HIF-1 to
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the HRE of the target genes. But, PKM2 itself is a hypoxia target gene since a hypoxia
responsive element (HRE) was observed in the intron 1 of PK-M2 [60]. PK-M2 promotes
the Warburg effect [61,62]. PK-M2 is identified in almost all the cancer cells and is essen-
tial for rapidly dividing cells since quicker energy harvesting is possible by shifting from
aerobic to anaerobic metabolism [63]. PDK1 (pyruvate dehydrogenase kinase 1) is also a
HIF-1 target gene. PDK1, which is a hypoxia target gene, inhibits the action of the enzyme
PDH (pyruvate dehydrogenase) which converts pyruvate to AcCoA (acetyl-co enzyme A).
Hence, pyruvate is unable to enter into the citric acid cycle and is trapped in the cytosol and
the rate of glycolysis is increased. This explains the Warburg effect and the relationship
between prolonged glycolysis and HIF-1 activation. So, in effect PK-M2 catalyzes the
conversion of PEP to pyruvate and PHD3 hydrolyzes PK-M2 and the hydrolyzed PK-M2
enters the nucleus and interacts with HIF-1α subunit and enhances the binding of HIF-1 to
the hypoxia responsive elements of the target genes. But, PK-M2 and PHD3 are hypoxia
target genes. Moreover, PDK does not allow pyruvate to enter into the citric acid cycle
and traps pyruvate in the cytosol. Pyruvate inhibits PHD which stabilizes HIF-1α , but
PDK1 itself is a HIF-1 target gene. Most of the glycolytic enzymes like GLUT1, LDHA,
ALDA etc. are the hypoxia target genes and this explains the feed forward mechanism
for HIF-1α activation and increased rate of glycolysis. PHD2 hydrolyzes HIF-1α and the
hydrolyzed HIF-1α is degraded by the VHL tumor suppressor protein. But, PHD2 itself is
a hypoxia target gene [64]. This feed-back inhibition acts a regulative control for hypoxic
response when normoxia is re-established. Thus, HIF-1:PHD2 linked transcription sets up
the appropriate HIF-1 signaling to face the hypoxic stress effectively.
3.4 Stress Response Pathways
In biology, almost all the knowledge and information is usually available as signaling
pathways. This information is unable to represent the multivariate interactions between the
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genes, even though it can give a pictorial representation of the univariate interactions. It is
also possible that two or more pathways can share the same genes or the same node. Thus,
a biological pathway gives a clear cut idea of the marginal relationship between different
genes in that pathway, but fails to provide information about how these genes interact glob-
ally when they are present in different pathways. The main aim of this work is to generate
a Boolean network whose state transitions realize the hypoxic stress response pathways.
The resulting Boolean network obtained shows dynamic behavior which is consistent with
the experimental results and observations from published literature [13, 65]. By incorpo-
rating the expert knowledge obtained from the biological pathways, the cardinality of the
search space of the network can be reduced. The main drawback of the pathway knowl-
edge is that it provides only partial information and that too restricted to a specific context.
By mathematically modeling the multivariate interaction between the genes in a pathway,
these networks can be used to differentiate between normal cell behavior and diseased cell
behavior. By working with the genetic regulatory networks instead of the biological path-
ways, the holistic behavior of the genes can be captured and the appropriate therapeutic
interventions can be developed. The aim of biological pathway modeling is to marginally
capture the causal interactions taking place inside a cell when a stimulus or stress is ap-
plied. Stress response pathways constitute an important set of pathways studied in the
biological literature. The main aim of adaptive stress response pathways is to understand
the transcription of cytoprotective genes in the presence of stress [16]. If a stress is applied
to a cell exogenously such as xenobiotic, radiation, heat etc. the cell responds via several
highly conserved adaptive stress response pathways that will try to attenuate the conse-
quences of this stress and re-establish the homeostasis. The rapid response of the stress
response pathways can be attributed to their special architecture. Basic components of this
architecture include a transcription factor, a sensor and a transducer. A schematic diagram
of the architecture of the stress response pathways is shown below [65] in Fig. 3.1.
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Figure 3.1: General scheme of stress response pathways
A transcription factor is a protein which binds to the DNA through the response ele-
ments within its promoter region and thus activates or upregulates the expression of the
target genes. During the absence of stress, the transcription factor is prevented from en-
tering into the nucleus with the help of a protein known as a sensor. It interacts with the
transcription factor in such a way that the transcription factor is sequestered in the cy-
toplasm. When a cell is faced by a stress, an enzymatic protein, transducer, transfers a
cue from a pathway which lies upstream of the sensor/transcription factor complex. The
transducer either modifies the transcription factor or modifies the sensor which destabi-
lizes the sensor/transcription factor complex. The activated transcription factor then enters
the nucleus and is able to upregulate the target genes.
3.5 Boolean Network Modeling
Given two genes/proteins A and B and binary values a,b ∈ {0,1}, we define the term
pathway segment A
t:a,b−→ B to mean that if gene/protein A assumes the value ′a′ then
gene/protein B transitions to ′b′ in no more than t subsequent time steps. A pathway is
defined to be a sequence of pathway segments of the form A
t1:a,b−→ B t2:b,c−→C. A Boolean Net-
work (BN), ϒ= (V,F), on n genes is defined by a set of nodes/genes V = {x1, ...,xn}, xi ∈
{0,1}, i = 1, ...,n, and a list F = ( f1, ..., fn), of Boolean functions, fi : {0,1}n→ {0,1},
i= 1, ...,n. The expression of each gene is quantized to two levels, and each node xi repre-
sents the state/expression of the gene i, where xi = 0 means that gene i is OFF and xi = 1
means that gene i is ON. The function fi is called the predictor function for gene i. Updat-
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Figure 3.2: Hypoxia stress response pathways
ing the states of all genes in ϒ is done synchronously at every time step according to their
predictor functions. At time t, the network state is given by x(t) = (x1(t),x2(t), ...,xn(t)),
which is also called the gene activity profile (GAP) of the network. The prior biologi-
cal knowledge of the hypoxia stress response pathways is used to arrive at the Boolean
network describing hypoxia stress response activity. The Karnaugh map (K-map) reduc-
tion technique is used to obtain an update equation for each and every node [13, 65]. The
hypoxia stress response pathways is shown below in Fig. 3.2.
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The pathway segments from the pathways in Fig. 3.2 are given by:
Hypoxia
1:1,0−→ O2 (3.1)
O2
1:1,1−→ PHD2 (3.2)
PHD2
1:a,a¯−→ HIF1 (3.3)
HIF1
1:1,1−→ HRE (3.4)
HRE
1:1,1−→ PDK (3.5)
HRE
1:1,1−→ PHD2 (3.6)
PDK
1:1,1−→ PY RUVAT E (3.7)
PY RUVAT E
1:1,0−→ PHD2 (3.8)
HIF1
1:1,1−→ ROS (3.9)
ROS
1:1,0−→ PHD2 (3.10)
From the above described pathway segments, and applying the technique of K-map
reduction explained [13], the update equation for each and every gene is obtained. The
state space is defined as [PHD2,HIF,HRE,ROS,PDK,PYRUVATE]. This resulted in a set
of possible Boolean networks, out of which the one that matched the most to the prior
literature knowledge was chosen. The update equations are given below. From the set
of possible Boolean networks we chose the ones that appealed most to our biological
understanding and the resulting update equations are given below:
O2next = Hypoxia, (3.11)
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Figure 3.3: Digital equivalent of hypoxia stress response pathways
PHD2next = (PY RUVAT E +ROS) · (O2+HRE), (3.12)
HIFnext = PHD2, (3.13)
HREnext = HIF, (3.14)
ROSnext = HIF, (3.15)
PDKnext = HRE, (3.16)
PY RUVAT Enext = PDK. (3.17)
This Boolean network will have two different contexts based on the value of the hy-
poxic stress, i.e., when Hypoxia=0 and when Hypoxia=1. The resulting equations are
expressed as a digital circuit and shown in Fig. 3.3 The state transition diagrams result-
ing from the above equations for the two cases, Hypoxia=0 and Hypoxia=1, are shown in
Figs. 3.4 and 3.5 respectively.
In these transition diagrams, the genes in the binary state representation are ordered
as [PHD2, HIF, HRE, ROS, PDK, PYRUVATE] and the binary states are compactly rep-
resented by their decimal equivalents. For instance, the binary state (111100) would be
represented by the decimal number 60. The states of particular interest are the attrac-
tors as they give rise to the steady-state properties of the network. In Fig. 4, the state
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Figure 3.4: State transition diagram with hypoxia=0
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Figure 3.5: State transition diagram with hypoxia=1
of interest is the singleton attractor 32(100000). On the other hand, in Fig. 5, the state
space is partitioned. Hence the final attractor cycle will depend on the starting state,
one of them cycling through 47− > 3− > 17− > 28− > 62− > 47 and other through
63−> 15−> 19−> 29−> 30−> 63. This would lead to cyclical/oscillatory behavior
in the time domain response when Hypoxia = 1. There is a singleton attractor, 31(011111)
in both cases of Hypoxia = 0 and Hypoxia = 1 which is not biologically feasible. Spurious
attractors of this type do arise in Boolean network modeling. When such networks are
derived from pathway information, the ill-posed nature of the inverse problem makes the
appearance of spurious attractors even more likely. The equations derived were simulated
using MATLAB by giving an external stress input signal for a duration of 100 timesteps,
and both the input signal and the responses are shown in Figs. 3.6 and 3.7. From the plot
in Fig. 3.7, one can reasonably expect to see oscillations in the presence of hypoxic stress
similar to the p53-MDM2 oscillations induced by DNA damage. It would be interest-
ing to experimentally verify if this is indeed the case. In Fig. 3.7, the two time response
corresponds to the two steady-state attractor cycles.
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Figure 3.6: Time response behavior when hypoxia=0
3.6 Targeting Hypoxia in Cancer Therapy
Hypoxia is a feature of most solid tumors. It is known to promote malignant progres-
sion, metastatic capacity, resistance to chemotherapy and leads to poor patient prognosis.
In normal tissues, the oxygen supply will depend on the metabolic requirements [66].
However in tumors the oxygen requirement is way higher than the supply and this leads to
some areas in the tissue where there is inadequate oxygen. Increased levels of hypoxia are
consistently correlated with genetic instability, tumor progression and poor patient prog-
nosis [67]. Hypoxia is a very prominent characteristic displayed by solid tumors, since
rapidly dividing aggressive solid tumor development and progression demands a lot of en-
ergy. This energy demand makes oxygen become a limiting factor. As the tumor grows
to about 2-3 mm in diameter, the normal oxygen supply is unable to meet the increased
energy demand of cancer tissues. Tumor cells that are beyond the diffusion distance for
oxygen (>70µm) are exposed to low levels of oxygen. The cells adapt to this scarcity of
oxygen, by creating new blood vessels from the already existing blood vessels (tumor an-
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Figure 3.7: Time response behavior when hypoxia=1
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giogenesis) and also by increasing the glycolytic flux for easy and faster anaerobic energy
production. Moreover, an adaptive response is mounted through recruiting enzymes, tran-
scription factors and via triggering specific protein signaling cascades. HIF-1α achieves
the cellular response to hypoxia through activating the transcription of thousands of hy-
poxia responsive genes. Furthermore, HIF-1α functions as a master regulator of cellular
and systemic homeostatic response to hypoxia through activating transcription of several
genes including those involved in energy metabolism, angiogenesis, apoptosis and other
genes whose protein products increase the oxygen delivery or facilitate metabolic adapta-
tion to hypoxia. HIF-1α thus plays an essential role in embryonic vascularization, tumor
angiogenesis and patho-physiology of ischemic diseases. Finally, the alternatively spliced
transcript variants encoding different isoforms have been identified for this gene, although
the exact functions of the isoforms are currently unknown. HIF-1α activates the transcrip-
tion of genes that are involved in crucial aspects of cancer biology including angiogenesis,
cell survival, glucose metabolism and invasion [68]. One of the hallmarks of cancer is a
metabolic switch from the TCA cycle to Glycolysis as a main source of energy produc-
tion [36]. This is known as the Warburg effect and was observed by Otto Warburg in the
1920s. HIF-1α is also known to up-regulate enzymes involved in glycolysis. There is lot
of work in the literature that discusses the importance of hypoxia in cancer biology. It has
been long recognized that therapeutically targeting hypoxia might alleviate some of the
negative characteristics associated with cancer cells.
The identification of targets that mediate response in the hypoxic cell in response to
hypoxia is important because inhibition of these targets could lead to cell death. The main
oxygen-responsive signaling pathways that mediate cellular response to hypoxia involve
the HIF family of transcription factors, unfolded protein response (UPR) and mammalian
target of rapamycin (mTOR) [69]. In conditions of severe hypoxia, HIF-1α is activated
and leads to the regulation of HIF family of transcription factors which includes VEGF
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(angiogenesis), GLUT1 (glucose transporter), almost all enzymes involved in glycolysis.
Severe hypoxia also leads to mistakes in protein folding which contributes to ER stress
or UPR. During UPR, the cell tries to conserve energy by stopping translation of proteins
and directs all misfolded to proteins to undergo degradation in the endoplasmic reticulum
(ER). One of the pathways through which UPR is mediated is through the PERK pathway.
Hypoxia also causes a drop in ATP levels which mediates a response through the mTOR
pathway. Metabolic reprogramming in tumor cells called the Warburg effect is in part
mediated by HIF-1α and mTOR. But this switch is also regulated by p53 and PI3K/Akt
pathways as well. The downstream effects of these mediate apoptotic or cell-survival
regulators.
3.7 Boolean Model and Targeted Therapy Under Persistent Hypoxia
We used results published in the literature to get all the necessary pathways [69–
72].Here we try to model a hypoxic cell considering three major phenomena- apopto-
sis, cell survival and the Warburg effect. The pathways related to these phenomena are
included in the above figure. After modeling based on the Boolean network explained pre-
viously, we apply the different drug combinations to see which one provides the maximum
benefit. Benefit is measured in terms of three quantities a) up-regulation of average activ-
ity of Bad (Bcl-2 associate death promoter)gene, b) down-regulation of average activity of
Bcl-2 (B-cell CLL/lymphoma 2) gene and c) down-regulation of ATP produced through
fermentation (Warburg effect). Effective drug combination is defined as the combination
with maximum benefit, in terms of the factors described above and minimum number of
drugs in order to reduce the side effects of treatment.
3.7.1 Description of Drugs
There are 8 drugs used in this simulation. We include a brief description of each.
a) Metformin: An anti-diabetic drug suspected to have anti-tumor properties. In the path-
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way it is shown to activate AMPK.
b) Dorsomorphin: A cell-permeable pyrrazolopyrimidine compound that inhibits AMPK
kinase activity.
c) Dimethyloxalylglycine: Dimethyloxalylglycine is a cell permeable prolyl-4-hydroxylase
inhibitor, which upregulates HIF-1α by suppressing the activity of prolyl-hydroxylase.
d) Echinomycin: Echinomycin is a peptide antibiotic. It intercalates into DNA at two spe-
cific sites, thereby blocking the binding sites of HIF-1α .
e) Avastin: Bevacizumab (trade name Avastin, Genentech/Roche) is an angiogenesis in-
hibitor, a drug that slows the growth of new blood vessels. It is licensed to treat various
cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only),
kidney and ovarian.
f) Pottasium dichloroacetate: Salts of DCA have been studied as potential drugs because
they inhibit the enzyme pyruvate dehydrogenase kinase.
g) Bromopyruvic acid: It is an inhibitor of hexokinase which is an enzyme involved in the
first step of glycolysis.
h) Sodium oxamate: Structural analog of pyruvate, inhibits L(+)-lactate dehydrogenase
and derails the entire gluconeogenic pathway.
The major pathways along with the drugs that act on these are shown in Fig. 3.8. The
drugs are shown in green rectangular boxes in the above pathway diagram. We have used
the following abbreviations PDC ( Pottasium dichloroacetate), BA (Bromopyruvic Acid),
SO(Sodium Oxamate), DMOG (Dimethyloxalylglycine). We did not abbreviate the name
of the drugs Metformin, Dorsomorphin, Echinomycin, Avastin. We modeled the pathways
in Fig. 3.8 as a Boolean model to simulate the effects of the various drugs.
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Figure 3.8: Pathway diagram incorporating pathways from apoptosis, cell-survival and the
Warburg effect
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Table 3.1: Effective drug combinations
Dorsomorphin DMOG Echinomycin Avastin PDC BA SO
0 0 0 0 1 0 1
1 0 0 0 0 0 1
1 0 0 0 0 1 0
0 1 0 0 1 0 1
1 0 0 0 0 1 1
1 0 0 0 1 0 1
1 0 0 0 1 1 0
1 0 0 1 0 0 1
1 0 0 1 0 1 0
1 0 1 0 0 0 1
1 0 1 0 0 1 0
1 1 0 0 0 0 1
1 1 0 0 0 1 0
3.7.2 Example Simulation
We consider a case of persistent hypoxia and no mutations and see how to intervene
in such a system. We will choose a starting state that is unfavorable to the system and see
what kind of intervention is best. Let the starting state correspond to Hypoxia=1, ROS=1,
GF=1, GFBP=0, Lactate=1, VEGF=1, Bad=0, Bcl2=1. We will assume random states for
the other variables in the system. We simulated for all 192 drug combinations. We have 8
drugs and this corresponds to 28=256 combinations. We however ignore the combinations
where Metformin(AMPK activator) and Dorsomorphin(AMPK inhibitor) are both present
so that eliminates 64 drug combinations, this leaves us with 192 (=256-64) combinations.
As mentioned earlier the effective drug combination is defined as one provides the maxi-
mum benefit. Benefit is measured in terms of three quantities a) up-regulation of average
activity of Bad, b) down-regulation of average activity of Bcl-2 and c) down-regulation
of ATP produced through fermentation (Warburg effect). Effective drug combination is
defined as the combination with maximum benefit, in terms of the factors described above
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and minimum number of drugs(3 maximum) in order to reduce the side effects of treat-
ment. We only show the drug combinations which yieded maximum benefit, there are
other drug combinations which yielded a overall positive effct but was lesser than the
benefit provided by the combinations in Table 3.1. Table 3.1 shows all favorables drug
response where all the three criteria were found to be satisfied, and the effective gain in
each category was the highest, with minimum number of drug combinations.
3.8 Discussion
In Table 3.1, we identify combinations of 2 or 3 drugs are more effective in tackling
the problem at hand rather than administering a single targeted drug. Dorsomorphin, an
AMPK inhibitor has been shown to reverse the mesenchymal phenotype of breast cancer
intiating cells [73]. As explained in [74], EMT or Epithelial to Mesenchymal Transition
is an important feature of carcinogenesis and Dorsomorphin has been shown to reverse
the Mesenchymal phenotype. DMOG is an indirect activator of HIF-1α . It works by in-
hibiting PHD’s and stabilizing HIF-1α . It is also known to upregulate VEGF, GLUT1,
however it does not increase mRNA levels of HIF-1α [75, 76]. Fannale et. al were able to
experimentally validate that hypoxia negatively regulates breast cancer cell growth during
short term in vitro exposure [77], this can be achieved by adding DMOG to stabilize HIF-
1α . They also noticed that it led to changes in DNA damage repair pathways which can
induce apoptosis or necrosis. Since DMOG upregulates GLUT1 which increases uptake
of glucose [76], this can be counteracted by adding BA (Bromopyruvic Acid), SO(Sodium
Oxamate) [78, 79]. Dorsomorphin is a known inhibitor of Bone Morphologic Protein
(BNP) whose role in cancer is contested as pro- or anti-tumor, but they are known to
induce angiogenesis [80, 81]. Our results suggest that using these drugs in combination
will prevent angiogenesis and since Dorsomorphin also affects AMPK it will also down-
regulate PI3K/Akt pathways. We notice that Echinomycin (an HIF-1α inhibitor) did not
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appear in any of the favorable combinations which had only 2 drugs. Echinomycin al-
ways appreared in combinations with two more drugs as shown in Table 3.1. This has
been experimentally seen and suggested that inhibiting just HIF-1α alone may not be suf-
ficient to halt angiogenesis and tumor growth. Hence, HIF-1α inhibitor needs to be used
in combination with other drugs that are unfavorable to the tumor microenvironment [82].
Anti-angiogenesis therapy has shed new light for cancer treatment but its effectiveness is
still not completely validated [83]. It has been experimentally validated that glycolysis
inhibitors aid the anti-VEGF treatment of Avastin in coloretal cancer [83]. One reason for
this evidence points to the fact that one outcome of hypoxic environment is resistance to
Avastin. In [83] they use BA (Hexokinase II inhibitior) in combination with Avastin to
get favorable outcome in terms of tumor volume and survival. Our boolean model pre-
dicts that this drug combination along with Dorsomorphin (BA+Avastin+Dorsomorphin)
or just Dorsomorphin with BA leasds to favorable outcomes. The reason for newer drug
combinations is because when simulations are performed they are repeated under differ-
ent cellular conditions. Hence, the combination needs to be specifically tailored for each
patient. Additionally, we also see that Avastin in combination with Sodium oxamate and
Dorsomorphin will also be an effective combination. Sodium Oxamate is known to be
an inhibitor of glycolysis [84, 85]. It was also seen that Avastin by itself will not lead
to favorable outcomes as compared to using it with other drugs in combination [86]. Di-
choloroacetate is a used for cancer therapy as suppressor of Warburg effect [87]. It is one
of the characteristics of cancer cells whereby they use Glycolysis (even in presence of
oxygen) to meet the majority of their energy needs. Dichloroacetate works by inhibiting
the enzyme pyruvate dehydrogenase kinase (PDK), increases the flux of pyruvate into the
mitochondria, promoting glucose oxidation over glycolysis. This reverses the suppressed
mitochondrial influenced apoptosis in cancer and results in suppression of tumour growth
in vitro and in vivo [87]. Here our model predicts drugs in combination with other drugs to
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treat cancer, which might be required since cancer cells have ability to bypass blockades
through other pathways. Epidemiological studies of Metformin, an anti-diabetic drug have
been suggested to have anti-cancer properties. Table 3.1 does have a single drug combina-
tion that has Metformin in the drug cocktail. Simulations with Metformin in combination
with other drugs yielded conflicting results. By conflicting results we mean that the re-
sponse was better by treating with Metformin in some cases and opposite in some other
cases. All the drug combinations shown in Table 3.1 without Metformin in the combina-
tion, gave a positive effect on treatment for the different starting conditions. We made a
literature survey to the check this ambiguity. We found that current preclinical and clin-
ical knowledge suggests that patients exhibiting hyperinsulinemia and tumors expressing
insulin receptor, LKB1 and TSC2 would only benefit from metformin but not others with
normal insulin levels and tumors lacking expression of insulin receptor (INSR), LKB1 and
TSC2 [88]. The gene LKB1 was not part of the BN model presented, it is brought into dis-
cussion due to the role it plays in activating AMPK. Metformin also acts to activate AMPK
and inhibit mTOR. So LKB1 upregulated in a Boolean model implies that AMPK is also
upregulated. However, the direct, insulin-independent effects of metformin originate from
LKB1-mediated activation of AMPK and a reduction in mTOR signaling and protein syn-
thesis in cancer cells. So the gene LKB1 was used to emphasize one of the mechanisms
through which Metformin acts to suppress mTOR. It has also been experimentally vali-
dated that Metformin’s actions varies based on the level of glucose. A recently published
work suggests that clinical trials of Metformin have yielded conflicting results [89] further
complicating the issue. Some studies point to AMPK as a tumor suppressor, whereas oth-
ers seem to suggest that it can be a promoter of tumor growth. We are encouraged, at this
point that the predictions made by our model is supported by data from real world.
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3.9 Concluding Remarks
Cancer cells are known to thrive in altered micro-environmental niches, including in a
hypoxic nitch. We have investigated via simulations the dynamics and response of cells
to hypoxia while also incorporating other major pathways that may be altered at hypoxic
stages. The biological pathways involved in cell growth and metabolic regulation were
mapped to a Boolean network. The equivalent digital circuit was used to identify drug
combinations that may be most effective in reducing the negative effects of Hypoxia while
giving maximum advantage. We incorporated the drug intervention points into our model
allowing us to test different combination therapies in terms of their efficacy in mitigating
the effects of faults in the network. Although the predictions from the current model we
developed to ameliorate hypoxia based tumor aggressiveness is encouraging, as it agrees
with several of the drugs used in current cancer therapy, we however need to proceed
with caution in the sense that some of the drug combinations suggested here may still fail
to work. This may be due to cross-talk with other pathways, feedback loops and other
molecules directly influencing the pathways in question and other mutations that might
be present. Nevertheless, this is a good starting point where there is agreement between
theoretical simulation, albeit literature based and real world. This we believe can help us
fast-track to test optimal intervention techniques.
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4. INTERVENTION UNDER UNCERTAINTY IN GENE REGULATORY
NETWORKS
4.1 Introduction
The primary goal in translational genomics is to construct a model of gene regula-
tory networks such that the model class a) incorporates rule-based dependencies between
genes that allow to study the global network dynamics, b) is able to cope up with uncer-
tainty in model selection and c) allows to design, implement and test effective therapeutic
strategies for intervening in gene regulatory networks (GRNs). Considering a model-based
approach, with an engineering perspective, an ”effective strategy” can be formulated as the
optimal solution to an optimization problem over the costs associated with each strategy,
where the cost is computed within an assumed model. Most previous studies have mod-
eled these systems under the assumption of perfect knowledge of the state transition rules.
This however, is not the case especially when dealing with biological systems owing to the
inherent complexity in understanding the response of the system to various stimuli under
various cellular conditions. The dearth of knowledge about the true dynamics of the sys-
tem is due to limited availability of data and costly experiments involved to generate such
data. The available information is usually on a local scale in the form of biological path-
ways. Additionally, variation across biological system is too confounding to come up with
the exact dynamics for such systems. Nonetheless, the existing knowledge, i.e. signaling
pathways, can be utilized to impose some constraints on the dynamics of the system. This
can lead to an uncertainty class of dynamical systems, rather than one single (and perhaps
inaccurate) model and optimize an objective function across the entire uncertainty class.
The solution to the optimization function will determine the optimal control strategy for
the system.
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Previously biological systems were modeled under the Markovian dynamical systems
framework as Boolean Networks (BNs) and its probabilistic variant Probabilistic Boolean
Networks (PBNs). PBNs have an advantage over BNs to account for stochastic state tran-
sitions. As a dynamical system there will change of state of the system which are called
transitions. Associated with each state change is a probability value defined the transition
probabilities. The transition rules in a BN/PBN can be characterized using a Markov chain
with known transition probability matrix (TPM). For a Markov chain, the TPM describes
the complete dynamics of the system. For these models, optimal intervention strategies
have been designed assuming that the information about the transition probabilities in the
system is known or can be generated with some uncertainty in them [5–10]. To refine
these models, prior knowledge in the form of pathways which gives the relational regu-
lation between a pair of genes/proteins is incorporated into the model [3, 65]. However,
these models were deterministic in nature. Furthermore, in these models the mutations
were identified and corrective interventions designed based on the signature of chosen
downstream genes.
We are interested in modeling a GRN as a Markov Decision Process (MDP). The the-
ory for analysis and control of MDP is very rich. The reader is referred to [4] for detailed
discussion on this topic. In this current work, prior biological knowledge is incorporated
in the form of biological pathway information, but with some uncertainty. The uncertainty
in the regulation of pathways is defined as a prior probability distribution is defined over
the system. The parameters of the distribution, which determines its shape expresses the
confidence on this prior knowledge. This information expressed over the pathways is used
to generate a family of TPMs, which defines the complete dynamics of the model. The
observations from the true system is used to update and reduce the size of the uncertainty
class of the designed model. The system is also assumed to have a true underlying tran-
sition matrix φ˜ (unknown but state observable). Since intervention is the ultimate goal of
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modeling GRN’s, an optimization framework is defined to estimate an optimal action at
each state. This action is optimal for the model determined by the prior defined over the
system. The objective function for the optimization problem is the expected cost relative
to the probability distribution over the uncertainty class and formulate an optimal Bayesian
robust intervention policy minimizing this cost function. Since the model will be updated
at every time epoch the designed intervention will be non-stationary and adaptive.
The theory of optimal Bayesian intervention in Markovian systems goes back to 1950s.
Bellman [90] considered the two-armed bandit problem with discounted cost and used the
term adaptive control for process with unknown transition probabilities. He proposed
the solution for this problem could be obtained by equivalently formulating it as a dy-
namic program. Then, Martin [91] extended these concepts to apply control theory to
systems where the system transition probabilities are unknown, but can be estimated us-
ing observations about the system states. The fundamental theory of optimal Bayesian
intervention in Markovian system has been recently applied to a Markovian gene regula-
tory networks [11], in which a gene regulatory network is modeled by a Markov chain.
Nonetheless, owing to incompleteness and partial knowledge, it is virtually impossible to
have one single TPM that represents the system completely. This uncertainty in the system
is expressed as a family of probability distributions. The parameters of the probability dis-
tribution function is known as hyperparameters. The initial parameters of the distribution,
also known as prior hyperparameters are updated based on observation from the system to
obtain the posterior hyperparameters. Conjugate distributions are probability distributions
in which prior and posterior belong to the same family of distributions. Then, instead of
dealing with the prior and posterior distributions we need to keep track of only the hy-
perparameters of the prior and posterior distributions. We consider two such distributions
to express our uncertainty about the biological system under consideration- Dirichlet and
Beta distributions. The optimization framework is based on Bellman’s Principle of Op-
69
timality. It was however, observed that the method suffers from extreme computational
and memory requirements, even for network of reasonable size. Hence, we also designed
sub-optimal methods so that the intervention problem can be solved much faster with rea-
sonable performance. The section is divided into 3 major topics- Model Convergence,
Bayesian Optimal Intervention and Bayesian Sub-optimal Intervention.
4.2 Problem Description: Modeling
A Boolean network (BN) is composed of n nodes, V = (v1,v2, .....vn) and a list of
Boolean functions, F = ( f 1, f 2, ..... f n) describing the functional relationships between
the various nodes. Each of these nodes represent a gene/protein. A Boolean formalism is
used to represent the state of each gene. The expression of each gene is quantized to two
levels, and each node vi represents the state/expression of the gene i, where vi = 0 means
that gene i is OFF and vi = 1 means that gene i is ON. At time k, the network state is given
by v(k) = (v1(k),v2(k), ...,vn(k)), which is also called the gene activity profile (GAP) of
the network. The idea of GAP is same as the state of the system, since it consists of the
states of all the genes in the Boolean network. The Boolean function f i : (0,1)pri → (0,1)
determines the value of node i at time k+ 1 given the value of its predictor/parent nodes
(pri) at time k. We assume a synchronous update scheme for the nodes which means
that all the nodes of the BN update simultaneously. The complete dynamics of the BN is
defined by the transition probabilities between all the states. This is usually represented in
the form of a TPM. Thus, given a system in a particular state i, the next state j of the system
is dependent on the transition probabilities vector associated with state i. Since these
transitions are stochastic in nature and has Markov property we can represent the BN by
an equivalent Markov chain. The TPM of a BN denoted by P, gives all information about
the transition probabilities between the states of the system. Since the state of the genes are
represented by 0 or 1 we use the decimal equivalent to represent the GAP of the system.
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For a system with n genes, the GAP varies from 0 to 2n−1. Let Zk ∈ S,k = 0,1, ..2n−1
be the stochastic process that defines the transitions for this system. Starting from a state
i ∈ S the system moves to a new successor state j ∈ S with to a state transition probability
Pi j = P(Zk+1 = j|Zk = i). This value corresponds to the (i, j)th element of the TPM.
The sum of the elements of each row of the TPM which corresponds to a state i adds up
to 1, since it is a valid probability distribution. The important task thus, is to generate
a family of TPMs along with the entries that reasonably explains the dynamical system
under consideration. Once a model is available which describes the system based on our
current knowledge we will intervene the system externally to affect the states visited by it.
4.2.1 Uncertainty Quantification
If we assume that we have complete knowledge of the system then all the entries of
the TPM are fixed entries. Since such knowledge in a biological system is partial and
incomplete, it is not possible to determine the exact transition probabilities i.e, there is
an uncertainty about the transition probabilities and hence the next state of the system.
Instead of having a fixed entry for each element of P, we define a probability distribution
expressing uncertainty in the system transition probabilities. This will give rise to a family
of TPMs rather than just one. Two models used to quantify this uncertainty are discussed.
a) The first model quantifies the uncertainty over the state (GAP) transition probabilities.
b) The second model expresses the uncertainty over each node (gene) transition probabil-
ities.
In the first model the uncertainty is directly expressed over the state transition probabilities
of the TPM. We can associate with each state i, an uncertainty probability distribution of
transition probability to the successor state j which will correspond to a row of the TPM.
In the second model instead of expressing the uncertainty over the GAP, it is defined over
each gene (node) of the network. For each gene/node (vk,k ∈ (1, ...n)), a conditional prob-
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ability table Ck,k ∈ (1, ...n) is defined. These tables gives the probability of the next state
of the gene of interest (vi) given the state of the genes predicting gene i (pri). Previously,
in this dissertation the node transition probabilities are considered to be deterministic- 0
or 1, but now a probability distribution is defined over each of these transition probabili-
ties. Samples from these distributions can be appropriately combined to obtain a family
of TPMs which will represent our uncertainty class. A specific case of the model TPM re-
ferred to as expected TPM is discussed in Section. 4.3.4. It is calculated from the expected
value of all the uncertainty distributions over the transition probabilities. This TPM will be
stochastic in nature. As more information about the system is obtained, the hyperparame-
ters of the distribution is updated so that mean of the distribution is as close to the actual
transition values in the true system. In the ideal case of variance of the distribution being
zero, the probability distribution will be a point distribution at the mean value defined by
its parameters. This model will represent the true system. The primary difference in the
approaches of the two methods is one defines the uncertainty over the GAP of the network
and the other one defines the uncertainty over each node (gene) of the system.
4.3 Nominal Model Formulation
We will discuss about how the uncertainty class is defined and how these models con-
verge to the true model. These models will also be the basis for the intervention problems
discussed from Section 4.4 onwards.
4.3.1 Dirichlet Distribution Prior Model: Uncertainty Over State Transitions
Dirichlet distribution denoted by Dir(α), is a family of continuous multivariate proba-
bility distribution parametrized by a vector α of positive reals. It is a multivariate gener-
alization of the Beta distribution. The parameters of the distributions are referred to as the
hyperparameters. The transition matrix (P) gives the probabilities of transitioning from a
given state i to the next state j under action a expressed as Pi j(a). We express the uncer-
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A 
B 
Figure 4.1: 2-gene toy example

AB AB AB AB
AB α11 α12 α13 α14
AB α21 α22 α23 α24
AB α31 α32 α33 α34
AB α41 α42 α43 α44

Figure 4.2: Uncertainties in the state transition probabilities as parameters of Dirichlet
distribution
tainty in the state transition probabilities as a conjugate family of probability distributions
over the uncertainty class where each row (state) of the TPM follows a Dirichlet distribu-
tion with parameter vector α . Assuming that the rows of the TPM are independent, the
posterior probability distribution will again be a Dirichlet distribution with updated pa-
rameter vector α . Thus, the uncertainty in the system is expressed directly over the state
or gene activity profile of the system. The reason for choosing a Dirichlet distribution is
since that the GAP of the system is distributed multinomially, a Dirichlet distribution is a
conjugate prior for the Multinomial distribution.
Since the probability distribution is defined over the GAP for a system with n genes the
size of the parameter matrix will be 2n×2n. Every time the system state changes for state
i to state j the corresponding value of αi j is updated. For the 2-gene system if Fig. 4.1 the
size of the α matrix will be 4 × 4 as shown in Fig. 4.2. Each row of the matrix in Fig.
4.2 gives the parameters of the Dirichlet distribution used to obtain the various transition
probabilities from the state corresponding to that row.
73
4.3.2 Beta Distribution Prior Model
Beta distribution denoted by Beta(α , β ) is a family of continuous probability distri-
butions defined between [0, 1] parametrized by two positive shape parameters α and β .
Instead of assuming a prior distribution over transitions between states we express the
prior distributions over the parents and child in the network i.e, over each node of the
network. We assume that once the status of the parents are completely known the state
of the child is uniquely determined and is not influenced directly/indirectly by the other
nodes. This comes from the assumption that our BN has the property of Bayesian Nets.
Every node in a bayesian net has an associated conditional probability transition (CPT) ta-
ble which quantizes the direct influence of parents on the child node. At any given instant
the gene i is either ON or OFF due to the boolean formalism we have adopted. Consider
the pathway and the associated CPT table for gene C as shown in Fig. 4.3. A and B are
the parent genes, while C is the child gene. The state of C in the current step depends
on the states of A and B in the previous time step. The uncertainty in these transition
probabilities is expressed in terms of Beta distribution parameters α’s and β ’s as shown
in Fig. 4.4. In Fig. 4.3, the letters A, B and C correspond to the genes and in Fig. 4.4 the
letters a, b, c and d correspond to the mean value of the probabilities. The meaning of
the entry in row 1 of the table is P(Ck = 0 | Ak−1 = 0,Bk−1 = 0) = a which implies that
P(Ck = 1 | Ak−1 = 0,Bk−1 = 0) = (1−a), since it is a Bernoulli distribution. The symbol
P refers to the mean or expected value of the transition probability. Similarly, the other
entries in the table will correspond to the other states for the predictors (A and B) and
state of the child gene (C). Such CPT tables will always have 2 columns (state 0 or 1 of
child gene) and the number of rows is 2pri , where pri is the number of predictors/parents.
The reason for using a Beta distribution to express the uncertainty in the CPT table is be-
cause Beta distribution is a conjugate prior for Bernoulli distribution. In this case since the
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A
B
C
Figure 4.3: General layout pathway regulation conditional probabilities

C
AB α1,β1
AB α2,β2
AB α3,β3
AB α4,β4


C C
AB a (1−a)
AB b (1−b)
AB c (1− c)
AB d (1−d)

Figure 4.4: Uncertainties in gene regulation as parameters of beta distribution and its mean
value
uncertainty is expressed over pathways where the child can have values 0 or 1, we need
to keep track of only parameters of state 0 of the child since the parameters of state 0 is
related to state 1 by α1 = β0 and β1 = α0 due to mirror-symmetry property. Thus, for
every row in a CPT table a unique pair of α and β will specify the dynamics completely.
Similarly, there will be CPT table associated with each node of the boolean network.
4.3.3 Hyperparameters Update
The purpose of creating an uncertainty class is to represent our limited knowledge
about the system. But as our understanding of the system improves we would like to up-
date the hyperparameters of the distribution and reduce the size of our uncertainty class.
One of the biggest challenge in bayesian work is the design of prior that represents the
system. This itself is an area of research and the readers are referred to [92] and refer-
ences therein for more exposure to the topic. We will be discussing the whole premise of
the problem with uniform priors which represents the condition where the value of all the
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  A 
  D  C 
  B 
Figure 4.5: 4 gene network for simulation results
hyperparameters equals 1. This corresponds to a condition where we have no knowledge
or understanding of the system. However, the same procedure can also be applied to other
prior values as well. We consider the 4-gene network shown in Fig. 4.5 for our simula-
tions. The dynamics of this network is defined by the true but unknown TPM (φ˜ ) given
in Table. B.1. We can say looking at Fig. 4.5 that Pa(A)=B,C, Pa(B)=C,D, Pa(C)=A,D and
Pa(D)=A,B, where Pa stands for Parents. We are only interested in the interactions and
not the nature of the interactions since it is a synthetic example. The starting uncertainty
hyperparameter matrix defined as αdiri and αβbeta are shown in Table. 4.1 and 4.3. The
update process for the uncertainty parameter matrix for both distribution depends on the
current state i and next state j. As an example we will consider the situation when the
system transitions from i=’0000’ and j=’1011’.
a) For Dirichlet distribution it is straight forward and the value of α corresponding to
the transition from ’0000’ to ’1011’ is incremented by 1, since this transition is observed
and counted as a success. The updated matrix is shown in Table. 4.2. After this we repeat
the whole process for the next time-step.
b) For the Beta distribution the update process is a little more complicated. We need
to calculate all Parents and Child combination and then update the values. The values of
parents are
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Table 4.1: Initial Dirichlet hyperparameters

1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

Table 4.2: Updated Dirichlet hyperparameters

1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

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Table 4.3: Initial beta hyperparameters
PPPPPPPPP(B,C)t−1
At 0
00 α1A=1,β1A=1
01 α2A=1,β2A=1
11 α3A=1,β3A=1
10 α4A=1,β4A=1
PPPPPPPPP(C,D)t−1
Bt 0
00 α1B=1,β1B=1
01 α2B=1,β2B=1
11 α3B=1,β3B=1
10 α4B=1,β4B=1
PPPPPPPPP(D,A)t−1
Ct 0
00 α1C=1,β1C=1
01 α2C=1,β2C=1
11 α3C=1,β3C=1
10 α4C=1,β4C=1
PPPPPPPPP(A,B)t−1
Dt 0
00 α1D=1,β1D=1
01 α2D=1,β2D=1
11 α3D=1,β3D=1
10 α4D=1,β4D=1
Pa(A=1)=0,
Pa(B=0)=0,
Pa(C=1)=0,
Pa(D=1)=0 and
the child values are A=1, B=0, C=1 and D=1. The CPT tables are maintained for the
condition when child = 0. So observinf a child = 0 is a success, while child = 1 is a
failure. In each of the CPT tables, if state of child = 0, then α values corresponding
to the above combination of parents are updated. If state of child = 1, then β values
corresponding to the above combination of parents are updated. The updated αβbeta is
shown in Table. 4.4.
4.3.4 Expected Transition Matrix
The expected transition matrix (ETM) gives the expected values of the transition prob-
abilities from state ’i’ to state ’j’, P¯i j(a) = E[Pi j(a)], which is used in Eq. (4.11),(4.12), to
be discussed later. The expectation is calculated over the entire uncertainty class. These
expected values are calculated using the mean of the uncertainty distributions defined by
78
Table 4.4: Updated beta hyperparameters
PPPPPPPPP(B,C)t−1
At 0
00 α1A=1,β1A=2
01 α2A=1,β2A=1
11 α3A=1,β3A=1
10 α4A=1,β4A=1
PPPPPPPPP(C,D)t−1
Bt 0
00 α1B=2,β1B=1
01 α2B=1,β2B=1
11 α3B=1,β3B=1
10 α4B=1,β4B=1
PPPPPPPPP(D,A)t−1
Ct 0
00 α1C=1,β1C=2
01 α2C=1,β2C=1
11 α3C=1,β3C=1
10 α4C=1,β4C=1
PPPPPPPPP(A,B)t−1
Dt 0
00 α1D=1,β1D=2
01 α2D=1,β2D=1
11 α3D=1,β3D=1
10 α4D=1,β4D=1
the parameter vector α for Dirichlet and parameters (α ,β ) for Beta distribution. For the
problems under consideration we assume that the networks have the property of bayesian
networks, i.e. given the state of the parents/predictors of a gene (g), the state of the gene g
is uniquely defined by its parents/predictors and it is independent of the state of the other
nodes/genes in the network. Thus, if we extend the same principle from node (gene) to
state we come up with the following relationship for probability of transition from state Sk
to state Sk+1
P(Sk+1|Sk) =
n
∏
g=1
P(vgk+1|Pa(vgk)) (4.1)
In the above equation the left hand side gives the probability of transition from state Sk
to state Sk+1 and the right hand side specifies this probability as product of probabilities
of individual gene probabilities given its predictors at the previous time step. So if we
calculate the expected values in Eq.(4.1), we calculate the expected values of transitions
from current state to next state. Thus, Eq.(4.1) can be rewritten as
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E(P(Sk+1|Sk)) = E
{ n
∏
g=1
P(vgk+1|Pa(vgk))
}
(4.2)
The factors inside the product sign are the probability distribution of the gene’s state
at time k+1 as a function of state of its predictors/ parents at a time k. Since this is a
design parameter fixed by the user we assume that these distributions are uncorrelated,
hence Eq.(4.2) can be written down as
E(P(Sk+1|Sk)) = E
{
P(v1k+1|Pa(v1k))
}
×
E
{
P(v2k+1|Pa(v2k))
}
n· · · ×E
{
P(vnk+1|Pa(vnk))
} (4.3)
Now each of the expectation in the right hand side correspond to the expected values of
transitions of individual genes given the state of its predictors. Thus, the expected transi-
tion probabilities from state ’i’ to state ’j’ has been broken down to individual products of
expected transition probabilities of individual genes gives the state of its predictors i.e, in-
dividual CPT tables. For a Dirichlet distribution with parameters (α1, α2, · · · , α2n) the ex-
pected value is given by
(
α1
2n
∑
i=1
αi
, α22n
∑
i=1
αi
, · · ·, αk2n
∑
i=1
αi
)
. For a Beta distribution defined by param-
eters (α ,β ) the expected value is given by αα+β . The ETM will be denoted by the symbol
φ and φi j(a) defines the probability of transitioning from state i to state j under the control
action a. Once we obtain the ETM we can conclude that P¯i j(a) = E[Pi j(a)] = φi j(a).
4.3.4.1 Dirichlet Distribution Prior: Expected Transition Matrix
As with any distribution Dirichlet distribution has a mean or expected value that is used
for computations as discussed in Section 4.5. We define the expected transition matrix,
ETM φ for this case as in Eq. (4.4).
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φ =

α11/A α12/A α13/A α14/A
α21/B α22/B α23/B α24/B
α31/C α32/C α33/C α34/C
α41/D α42/D α43/D α44/D

(4.4)
where A = α11+α12+α13+α14
B = α21+α22+α23+α24
C = α31+α32+α33+α34
D = α41 +α42 +α43 +α44. In this case the rows of the TPM are independent Dirichlet
distributions and altering one value of α will only alter the entries in that row.
4.3.4.2 Beta Distribution Prior: Expected Transition Matrix
The mean conditional probability transition matrix for the 2-gene system in Fig. 4.1
are shown in Fig. 4.6. In Fig. 4.6, a1, a2, b1 and b2 denotes the expected values of the
transitions which are calculated from the mean of the distribution function that we have
defined. Once such an information about all the genes in a specific network is available
they can be used to determine a unique ETM, φ . We take a 2-gene regulatory network
example shown in Fig. 4.1 to show how we evaluate the ETM, φ . Let the subscript 1 and 2
denote the respective probabilities for genes A and B. We use both the mean CPT’s in Fig.
4.6 to evaluate the mean transiton probabilities between the states. Thus, what we achieve
is we combine the probability distributions over the nodes into probability distribution
over the states. The ETM φ will be given by Eq. (4.5).
φ =

a1a2 a1(1−a2) (1−a1)a2 (1−a1)(1−a2)
a1b2 a1(1−b2) (1−a1)b2 (1−a1)(1−b2)
b1a2 b1(1−a2) (1−b1)a2 (1−b1)(1−a2)
b1b2 b1(1−b2) (1−b1)b2 (1−b1)(1−b2)

(4.5)
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( A A
B a1 1−a1
B b1 1−b1
) ( B B
A a2 1−a2
A b2 1−b2
)
where a1=α1/(α1+β1), b1=α2/(α2+β2), a2=α3/(α3+β3) and b2=α4/(α4+β4).
Figure 4.6: Mean conditional probabilities transition values for the system
We see here in comparison to Dirichlet distribution model the different rows of the
final ETM φ are dependent on each other which is a realistic feature. As more and more
information is available we update the values of α’s and β ’s and thus the error between φ
and φ˜ reduces with time.
4.3.5 Model Convergence
Let the true CPT tables for the 4 genes in Fig. 4.5. We use these true CPT tables to
construct the true TPM for simulations shown in Table B.1. We call this the true TPM
since for the actual system the probabilities are not defined as probability distribution but
instead by a single value expressing the transitions. In a real system we do not need to
construct any TPM since it has an underlying dynamics. We start with a uniform prior for
both the Dirichlet(α = 1) and Beta distribution (α = 1, β = 1). This ensures the expected
values of all initial entries in the CPT tables to be 0.5. The ETM will be of size 16×16,
with each entry equal to 1/16. If we have more information, informative prior should be
used for the hyperparameters so that the model converges with the true system faster.
We let the system evolve under its true dynamics given by the true TPM from one
state to another and update the hyperparameters of the distribution. We show the norm of
the distance between true TPM and ETM after 10, 100, 1000, 10000 100000 and 1000000
steps of simulation in Fig. 4.8. As we can infer the Beta distribution prior model converges
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PPPPPPPPP(B,C)t−1
At 0 1
00 0.85 0.15
01 0.25 0.75
11 0.35 0.65
10 0.05 0.95
PPPPPPPPP(C,D)t−1
Bt 0 1
00 0.8 0.2
01 0.35 0.65
11 0.25 0.75
10 0.1 0.9
PPPPPPPPP(D,A)t−1
Ct 0 1
00 0.95 0.05
01 0.2 0.8
11 0.2 0.8
10 0.05 0.95
PPPPPPPPP(A,B)t−1
Dt 0 1
00 0.9 0.1
01 0.25 0.75
11 0.25 0.75
10 0.1 0.9
Figure 4.7: True CPT values
at a faster rate than Dirichlet model. The value of the mean CPT tables and the expected
TPM after 100 and 10000 time-steps after the simulations are shown in Appendix B. We
see that as we have more and more observations the model CPT’s are very close to the true
CPT’s. It is verified that with 10 million time-steps the values of the model CPT’s were
very close to the true CPT’s.
4.4 Nominal Problem Formulation: Intervention
Intervention in Markovian systems refers to sequential decision making problems in
which actions taken at discrete time steps alter the underlying dynamics of the system.
The dynamics are altered in such a way that the controlled system spends more time in
good states than the uncontrolled system. To model the effect of interventions we assume
that the networks can be intervened using an external control vector of length m, c =
(c1,c2, ...cm). The control scheme of length m suggests that in the n gene network, only
m genes can be externally intervened. Since we are using a Boolean formalism to express
gene expression, it is intuitive to use a similar formalism for the control inputs as well, i.e.,
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Figure 4.8: Norm between true TPM and ETM
each ci ∈ (0,1). ci = 0 implies that the control i is absent and ci = 1 means that we need
to intervene by applying the control signal i. The control input is also represented by its
decimal equivalent C ∈ (0,1, ...2m−1). The control applied to the system influences the
transition probabilities and hence the TPM. To define the relationship between the TPM
without intervention and TPM with intervention we need to understand that what happens
in the event of external intervention in state i. When the system is externally intervened
the state i changes to i˜ and hence the new elements of the controlled TPM P(a) is defined
as
Pi j(a) = P(Zk+1 = j|Zk = i,C = a) =

Pi j,if a = 0,
Pi˜ j,if a 6= 0.
(4.6)
In the above equation a denotes the decimal equivalent of the control inputs, a∈ (0,1, ..2m−
1). The decision maker has the ability to observe the time evolution of the states over the
horizon which may be finite of infinite. At each time-step k, upon observing the state, the
decision maker chooses an optimal action a (as solution of an optimization problem) that
will subsequently alter the dynamics of the system. Associated with each current state i,
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the next state j and control action a a cost gi j(a) is accrued. This cost reflects our degree
of desirability of various states. The control action a is decided based on the total cost we
will accrue over the horizon by choosing different actions. An intervention policy, denoted
by µ , is a prescription for taking actions from set C at time k. This mapping does not have
to deterministic in nature but can be a function of history. However, we assume that we
have a deterministic policy that is optimal. We desire an intervention policy µ ∈M such
that the objective function
JµP (i) = limN→∞
Eµi
{N−1
∑
k=0
λ kgzkzk+1(a)
}
(4.7)
is minimized. We denote this optimal cost as J∗(i). λ is a discount factor and λ ∈ (0,1)
and determines the rate of convergence of the value. gzkzk+1(a) is an user defined cost
function dependent on current state zk, next state zk+1 and applied control action a. The
above formulation is called Discounted Cost Infinite Horizon Problem. This optimization
problem is solved by formulating a set of simultaneous functional equations and a mapping
T J : S→ R, obtained by applying the dynamic programming mapping to any function
J : S→ R for all i ∈ S defined by
T J(i) = min
a∈A
{
∑
j∈S
Pi j(a)gi j(a)+λ ∑
j∈S
Pi j(a)J( j)
}
(4.8)
The optimal cost function J∗ is a fixed point of the mapping T . The optimal policy can be
determined by the convergence, optimality and uniqueness theorems outlined in [93].
4.5 Optimal Bayesian Intervention
In real-world applications perfect knowledge of the TPM will be unavailable or too
expensive to acquire. So we characterize the system probabilistically and optimize with
regard to this uncertainty class as explained in the previous sections. The results in this
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section are derived in [91]. Let
Ω=
{
P : P is |S|× |S|,Pi j ≥ 0, ∑
j∈S
Pi j = 1 for all i, j ∈ S ,
denote the class of all valid uncontrolled TPMs (uncertainty class). The uncertainty about
the matrix P is characterized by a prior probability density pi(P). At every stage k of the
problem an observation is made immediately after applying the intervention and this in-
formation to update the prior probability distribution to a posterior distribution. We call
the combination of state and probability distribution (i,pi(P)) as a hyperstate. Hyperstate
completely defines the system since it has information on the current state of the system
and also the hyperparameters of the distribution specifying all the transition probabilities.
The posterior probability density, when the system transitions from state i to state j under
control a is given by
pi ′(P : i,a, j) =

cPi jpi(P),if a = 0,
c′Pi jpi(P),if a 6= 0,
(4.9)
where c and c′ are normalizing constants dependent on i, j and a. In this case however, all
the uncertainties in transition probabilities are defined over the biological pathways. Now
for the intervention problem, the equations for the problem formulated as an equivalent
dynamic programming needs to be redefined to incorporate this prior density as
JµP (i,pi) = limN→∞
Eµi,pi
{N−1
∑
k=0
λ kgzkzk+1(a)
}
, (4.10)
here the expectation is taken not only w.r.t to the random stochastic process but also the
prior probability pi . The goal is now to minimize this objective function. We denote
the optimal cost as J∗(i,pi). We can solve the above objective function by forming an
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equivalent dynamic programming as formulated above. The equations are defined as
T J(i,pi(P)) = min
a∈A
{
∑
j∈S
P¯i j(a)gi j(a)+
λ ∑
j∈S
P¯i j(a)J( j,pi ′(P : i,a, j))
}
, (4.11)
for all i ∈ S, where P¯i j(a) = E[Pi j(a)] w.r.t prior density pi . It has been proved that there
exists a unique bounded set of optimal costs J∗ satisfying
J∗(i,pi(P)) = min
a∈A
{
∑
j∈S
P¯i j(a)gi j(a)+
λ ∑
j∈S
P¯i j(a)J∗( j,pi ′(P : i,a, j))
}
, (4.12)
which is the fixed point of the operator T . Since both prior and posterior distributions are
chosen to be conjugate distributions, instead of keeping track of closed form expressions
of the probability distributions we just need to keep track of the parameters defining the
distributions. The distribution with which the variable is defined is called the likelihood.
The likelihood over the state transitions the likelihood is Multinomial distribution, while
the distribution over the regulation of a single gene (CPT table) is Bernoullis distribu-
tion. We consider two such models of prior probability distribution- Dirichlet distribution
(along with Multinomial likelihood) characterized by parameter α and Beta distribution
(along with Bernoullis likelihood) characterized by two parameters α and β to represent
the uncertainty class of the system. The Dirichlet distribution is expressed over the entries
of the TPM P, but the Beta distribution is defined over each node/gene of the network.
The pseudo-code for the control problem using probability distribution prior is shown in
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algorithm 4.5.1. The prior information could be the parameters of the Dirichlet or Beta
distribution.
Algorithm 4.5.1: INTERVENTION USING UNCERTAINTY CLASS MODEL(h)
Starting state(i), Prior in f ormation(h)
Cost f unction(gi j(a, j)), True unknown TPM(φ˜)
top :
a?← f (i,gi j(a, j),h)
Next state( j)← φ˜(a?, i)
hupdated ← f ′(i, j,h)
h← hupdated
i← j
goto top
In the above f and f ’ are used to indicate that the variable on the left is a function of
the arguments.
4.6 Q-learning
The proposed methods in the previous sections uses successive approximation to solve
for the optimal costs which determines the control action. These methods will fail if we
try to extend it beyond a small number of genes. The Beta model is even more computa-
tionally intensive than Dirichlet model due to the way the ETM (φ ) is being evaluated. We
are more interested in the Beta model since we can incorporate the uncertainty over the
pathways which is the prior knowledge available in biological systems. However, the more
computationally difficult task in this whole solution is solution using Dynamic Program-
ming which suffers from Curse of Dimensionality. For each time step, the total number
of computations to determine the optimal control action is (|A|× |S|)K , |A| is number of
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control actions, |S| is number of states, K is number of steps in successive approximation.
These computations increase exponentially with increase in number of states and becomes
intractable. To avoid these intractability issues we make use of approximate solutions to
solve for the costs. This is part of machine learning called Reinforcement Learning of
which we use a specific technique called Q-learning. Reinforcement learning principles
allow an agent to make good informed action at every time-step by just exploring the en-
vironment and observing the rewards for each state-action pair. By repeating the process
for a very long time and ideally for infinitely long the agent can gradually converge on
the estimates of values for each state that will allow the agent to act optimally. Here we
model the nominal problem as a infinite-horizon discounted cost seeking to minimize this
cost. Let J∗(i) denote the optimal expected discount reward as explained in Eq.(4.7) that
is achievable from state i. Let Q∗(i,a) denote the value of executing action a at state i
and then executing the optimal action from there on. J∗(i) and Q∗(i,a) are related to each
other and is denoted by:
Q∗(i,a) = min
a∈A
{
∑
j∈S
Pi j(a)gi j(a)+λ ∑
j∈S
Pi j(a)J∗( j)
}
, (4.13)
J∗(i) = min
a∈A
Q∗(i,a) (4.14)
The optimal Q-factor vector Q∗ is the unique fixed point of the mapping F defined for
all (i,a) by
FQ(i,a) = min
a,a′∈A
{
∑
j∈S
Pi j(a)gi j(a)+λ ∑
j∈S
Pi j(a)Q( j,a′)
}
, (4.15)
Eq.(4.15) is the same as Eq.(4.8). These two equations have the same computational
complexity. If we have accurate information about the system dynamics we can use a sys-
tem simulator to converge to the Q∗(i,a) for all i ∈ S and a ∈ A. Then this matrix is used
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to design the optimal action based on Eq.(4.14). For the time evolution of the dynamical
system the Q-values are updated until some convergence criteria is met. The update equa-
tion for Q-values for every state-action pair (i,a) when using a system simulator is given
by Eq. (4.6).
Qk+1(i,a) = (1−α)Qk(i,a)+α[gi j(a)+λ min
a′∈A
Qk( j,a′)] (4.16)
f or α → 0 as k→ ∞.
once the Q-values converge the optimal Q-value for the state-action pair can be esti-
mated as
Q∗(i,a) = Qη(i,a) (4.17)
4.7 Approximate Bayesian Intervention Using Q-learning
In this section we show and explain the modified Bayesian Dynamic Programming
equations to incorporate concepts from Section.4.5, 4.6. We again define a prior probabil-
ity distribution (both Dirichlet and Beta) over the system. Once the system makes transi-
tion from state i to state j according to applied action a and the TPM (φ˜ ), the prior prob-
ability function updated to obtain the posterior probability function as per Eq.(4.9). Now
the optimal solution J∗ is given by Eq.(4.12). We can relate J∗(i,pi(P)) to Q∗(i,a,pi(P))
as
J∗(i,pi(P)) = min
a∈A
Q∗(i,a,pi(P)) (4.18)
Q∗(i,a,pi(P)) = Qη(i,a,pi(P)) (4.19)
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Algorithm 4.7.1: APPROX. BAYESIAN Q-LEARNING(pi(P))
MAIN : Starting state(i),Prior in f ormation(pi(P))
Cost f unction(gi j(a)),True unknown TPM(φ˜)
η is no. o f iterations
k← 0
Determine expected transition matrix using pi(P)
subroutine : while k < η
Choose a random control action,ak
Apply random action ak to state i in ETM
and determine next state j
U pdate : Qk+1(i,a) = (1−α)Qk(i,a)+
α[gi j(a)+λ mina′∈A Qk( j,a′)]
k = k+1
i← j
goto subroutine
Q∗(i,a,pi(P)) = Qη(i,a,pi(P)),∀i ∈ S and a ∈ A
J∗(i,pi(P)) = mina∈A Q∗(i,a,pi(P))
a∗ = argmaxa∈AJ∗(i,pi(P))
Apply a∗ to actual system and
observe real transition to state j
U pdate prior to obtain posterior pi ′(P)
pi(P)← pi ′(P)
i← j
goto MAIN
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In all of the above equations P¯i j(a) = E[Pi j(a)] = φi j(a) so we use the expected tran-
sition matrix model to find the transitions on applying random control and updating Q-
matrix according to Eq.(4.6). The approximate Q-learning algorithm shown in algorithm
4.7.1 combines aspects of model-free and model-based learning. The algorithm 4.7.1 was
implemented for both Dirichlet and Beta prior and the discounted cost evaluated.
4.8 Cost and Convergence Simulation Under Control for a 4-gene Example
We consider a 4-gene network defined by the following true but unknown T PM, φ˜ . The
network is shown in Fig. 4.5. The predictors/parents (Pa) are known to be Pa(A)=(B,C),
Pa(B)=(C,D), Pa(C)=(A,D) and Pa(D)=(A,B). In a true biological system knowledge of the
system will determine the predictors. The system is modeled using the methods described
in Sections. 4.3.4.1 and 4.3.4.2 and it is shown here that modeling with a Beta prior gives a
lower expected cost in comparison to a Dirichlet prior. To make comparisons easier, both
the system such that the starting model is the ETM φ is same for both the models. This is
done by choosing a uniform distribution for both the Beta and Dirichlet distributions. This
tells us when we have very little or no prior knowledge about the system since we assume
all the transition probabilities are set to be equal. The starting uncertainty parameter matrix
defined as αdiri and αβbeta are shown in Table. 4.1 and 4.3. The update process for the
uncertainty parameter matrix for both distribution depends on the current state i and next
state j and also control a as discussed previously. On applying control a changes state of
system to i˜ and the next state is j. Thus, if we know current state i (after applying control
a) and next state j the updated matrices are obtained as explained. We show that the cost
is optimal in a Bayesian sense. This means over the whole uncertainty class our action
will be optimal, though it might be sub-optimal for a specific TPM. For this we draw 100
samples each from the Dirichlet and Beta distributions. This will be representative of the
uncertainty class and will be used to design 100 different TPM’s.
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4.8.1 Simulation
We simulated the network in Fig. 4.5 from all starting condition 0,1,2...15 and eval-
uated the average accumulated cost and the convergence between the true T PM (φ˜ ) and
model T PM (φ ). The algorithm was implemented as follows.
• The parameters used for optimal DP simulation are: λ = 0.2,K = 3.
The parameter used for sub-optimal Bayesian Q-learning are: initial Q-matrix=0,
γ = 0.8,α = η/(η+1),η = 10000.
The cost function gi j(a) is defined by gi j(a) =

0, if a = 0, j is good
2, if a = 0, j is bad
0.1, if a = 1, j is good
2.1, if a = 1, j is bad
The control action available was assumed to only down-regulate gene C if it is up-
regulated.
• We started with a uniform prior for both the dirichlet and beta distribution. The idea
was to show quicker convergence and lower cost scheme in the case of modeling and
having prior distribution over pathways (Beta) rather than having prior distribution
over the states (Dirichlet).
• Using the prior we evaluated the model ET M.
• Using this model ET M, we evaluated the optimal control action using the method
of successive approximation and Bayesian Q-learning.
• We applied this control action to the the true T PM which represents the true system
and observe a transition.
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Table 4.5: Comparison of costs across different methods
Method JbetaDP J
diri
DP J
beta
Q J
diri
Q
Cost 1.517 1.521 1.523 1.527
• This transition gives a discounted cost which is already predefined and this is added
to the previously accumulated discounted cost.
• Based on the above transitions the prior is updated to obtain the posterior which
gives us the model T PM. The norm of the distance between true system and model.
• The whole process is repeated for same starting condition multiple times (100) over
100 networks generated from the uncertainty class. Every time the simulation is run
the path is going to be different due to stochastic nature of the transitions. We then
average out the accumulated cost and norm between true system and model over all
initial starting states assuming them to be equally likely.
• The final cost and convergence plots are shown in Table 4.5 and Fig. 4.9.
4.9 Conclusions
In this section we developed a stochastic model of a GRN. The uncertainty over the
model were introduced as probability distributions over two critical aspects of the system,
namely the state and the nodes of the GRN. We showed that updating the model with data
from the system helps us to reduce the size of the uncertainty class and converge to the true
system. We also defined an optimization framework to estimate optimal control actions
over the uncertainty class. The estimated control action is going to be optimal over the
uncertainty class and not over every individual network. The optimal methods however,
suffered from extreme computational and memory complexities and we had to implement
sub-optimal methods to not only solve the problem in reasonable time but also to scale
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Figure 4.9: Convergence of model to true system across different methods
the size of the network to incorporate more number of nodes. The sub-optimal methods
worked reasonably well. We feel that this kind of work has a strong potential in context of
cancer genomics- both for network inference and network intervention.
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5. CONCLUSIONS
Traditionally, drug discoveries have been performed by identifying functionality of in-
dividual components, rather than looking at their overall systemic properties. Considering
only a few aspects of a complex system has led to very limited success in treating com-
plex diseases like cancer. Now over years of work it is evident that many of the complex
diseases are not caused by just one single factor- a gene, a protein, or biochemical reac-
tion, but a combination of many factors. With this is mind it becomes imperative to study
the global dynamical properties of integrated and interacting networks of biological com-
ponents. Systems biology is gradually becoming the norm to understand biology from a
holistic point of view. With the current advancement in biology including high-throughput
data (next-gen sequencing), more health related issues are being pursued from a genetic
angle. This effort has led us in recent years to catalog the human genome, and in a position
to amend the traditional methods of treating complex health problems.
Most of the work in biology so far has focused on understanding univariate interac-
tions. However, to understand genetic diseases including cancer it is important to focus
on the multivariate interactions in these systems. Biological systems are observed to show
circuit/ network like properties however, we have not exploited these properties for better
understanding until recently. Gene regulatory networks represent these biological systems
which are highly structured but incredibly complex to understand. With this in mind, it
is imperative to improve our understanding of gene-regulatory networks. There are many
aspects to systems biology, one of them being modeling and studying the dynamical prop-
erties of the gene regulatory networks, which has been the focus of this dissertation. This
systems based approach will aid and enhance our success in drug design and discovery by
finding good treatment strategy. This has been another focus in this dissertation.
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In this dissertation, logic synthesis is used to model and study the gene regulatory net-
works. The constructed models are used to determine the faults in the networks based
on the signature of few output genes. A similar approach was used to test drug efficacy
by measuring the profiles of downstream genes. These results can be used to determine
the faults and then based on the faults determine the optimal drug combination. To make
the models more realistic, stochastic nature of transitions are introduced and control algo-
rithms for these developed based on a Bayesian framework.
It is shown that the task of modeling of gene regulatory network is a non-trivial task.
The non-triviality of the task is due to the very limited understanding of the dynamics of
these systems. We have tried to circumvent this limitation by using prior knowledge in
the form of biological pathways as well as introduce uncertainty over the prior knowledge.
We have validated some of our simulation results using experimental results from other
researchers work. We have met with some success in this regard. This motivates us to
pursue this line of research in the future to validate the actual dynamical system as pre-
dicted by our model. This would however, require time-series data acquisition of the gene
regulatory network which we plan to pursue in immediate future.
Some of the research questions of immediate interests will be:
• Modeling for multiple fault scenario since there are multiple mutations/faults in a
network.
• Validating the dynamical model in vitro and in vivo.
• Validating the fault detection strategies.
• Validating the drug intervention strategies.
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APPENDIX A
DESIGNING A TEST SEQUENCE
As an example on how to obtain the test sequence let us consider the sequential circuit
shown in Fig. A.1.
Figure A.1: Digital equivalent of a circuit
Let us also assume that the internal state is known and is y1=y2=0. Let us determine
the test sequence that will determine the fault at location ’a’ s-a-1. Time frame 0: Since
y2=0 and we have the line s-a-1. As we need to propagate this fault we choose x=1 so that
the output of G4 is going to be 0 for normal circuit and 1 for faulty circuit. The internal
state is y1=0, y2=0/1. In the representation a/b, a corresponds to value in normal and b
corresponds to value in fault network. The output is z=1. Time frame 1: Since the state
y1 did not change we cannot produce a difference in the output between normal and faulty
110
network so we maintain x=1 and push the system to internal state y1=0/1, y2=0/1 and x=1.
Time frame 2: Since there is difference in state y1 between normal and faulty circuit we
can propagate this to z by choosing x=1 and z=1/0. Hence the test sequence x=’111’ will
determine the fault at ’a’ s-a-1.
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APPENDIX B
RESULTS OF SIMULATION FROM SECTION 4
We show the results of convergence in this section. Let us assume the true CPT tables
be given Fig. B.1. This true CPT tables will give a true TPM given in Table. B.1. The
mean CPT tables after 100 and 10000 time-steps are shown in Fig. B.2 and B.3. The
expected TPM after 100 and 10000 time-steps for Dirichlet and Beta models are shown
in Table. B.2, B.3, B.4 and B.5. It was seen that with more and more data the model
converged to true transition probabilities and the variance of the models was very small.
This means that the expected TPM is the same as the true TPM.
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PPPPPPPPP(B,C)t−1
At 0 1
00 0.85 0.15
01 0.25 0.75
11 0.35 0.65
10 0.05 0.95
PPPPPPPPP(C,D)t−1
Bt 0 1
00 0.8 0.2
01 0.35 0.65
11 0.25 0.75
10 0.1 0.9
PPPPPPPPP(D,A)t−1
Ct 0 1
00 0.95 0.05
01 0.2 0.8
11 0.2 0.8
10 0.05 0.95
PPPPPPPPP(A,B)t−1
Dt 0 1
00 0.9 0.1
01 0.25 0.75
11 0.25 0.75
10 0.1 0.9
Figure B.1: True CPT values
PPPPPPPPP(B,C)t−1
At 0 1
00 0.5714 0.4286
01 0.2 0.8
11 0.3125 0.6875
10 0.0625 0.9375
PPPPPPPPP(C,D)t−1
Bt 0 1
00 0.75 0.25
01 0.4 0.6
11 0.381 0.619
10 0.0405 0.9595
PPPPPPPPP(D,A)t−1
Ct 0 1
00 0.8 0.2
01 0.2308 0.7692
11 0.4167 0.5833
10 0.0789 0.9211
PPPPPPPPP(A,B)t−1
Dt 0 1
00 0.8 0.2
01 0.4615 0.5385
11 0.4118 0.5882
10 0.1325 0.8675
Figure B.2: Mean CPT values after 100 time-steps
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PPPPPPPPP(B,C)t−1
At 0 1
00 0.8303 0.1697
01 0.2399 0.7601
11 0.3625 0.6375
10 0.0492 0.9508
PPPPPPPPP(C,D)t−1
Bt 0 1
00 0.7655 0.2345
01 0.3672 0.6328
11 0.2465 0.7535
10 0.1032 0.8968
PPPPPPPPP(D,A)t−1
Ct 0 1
00 0.9544 0.0456
01 0.2048 0.7952
11 0.203 0.797
10 0.0482 0.9518
PPPPPPPPP(A,B)t−1
Dt 0 1
00 0.9197 0.0803
01 0.2515 0.7485
11 0.2397 0.7603
10 0.0985 0.9015
Figure B.3: Mean CPT values after 10000 time-steps
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